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CHAPTER I 
INTRODUCTION 
Malaria and Plasmodium 
In the 2013 World Malaria Report, the World Health Organization (WHO) 
reported that 97 countries around the world had ongoing malaria transmission, accounting 
for nearly 3.4 billion people at risk for contracting the disease. There were an estimated 
207 million malaria cases in 2012, with approximately 627,000 deaths. 77% of these 
deaths occurred in children under the age of five, meaning that malaria killed one child 
almost every minute during that year. This loss of life took place in spite of $2.5 billion 
of international and domestic funding, a number that the WHO suggests is less than half 
of what is actually needed to control the disease (WHO, 2013). 
This enormous toll on society is caused by an ancient, single-celled protozoan 
parasite of the genus Plasmodium. To date, there are five species of Plasmodium known 
to infect humans: P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi (Oaks, 
1991; Singh et al, 2004). Of these five, P. falciparum is considered to be the most deadly, 
while P. vivax is the most widespread (Li et al, 2001). Malaria is a vector-borne disease, 
and each of these species is transmitted to humans by female mosquitoes of the genus 
Anopheles (Oaks, 1991).  
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The life cycle of Plasmodium can be divided into three different stages: infection, 
multiplication, and transmission. Infection begins when a mosquito feeds on a naïve host 
and injects sporozoites into the host’s bloodstream. The sporozoites invade the liver cells, 
where, over the next 5-15 days, they multiply asexually to produce schizonts, with each 
schizont containing between 10,000 and 30,000 merozoites. Eventually the infected liver 
cells rupture, and the merozoites are released into the bloodstream, where they proceed to 
invade erythrocytes. Within the red blood cell, the merozoite starts an asexual 
reproduction cycle in which it first matures into a trophozoite and then into a schizont to 
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again produce more merozoites. When the red blood cell eventually bursts, these 
merozoites will infect new red blood cells, and the multiplication process will start again 
(Figure 1). The destruction of an increasing amount of red blood cells eventually leads to 
the symptoms that characterize the disease malaria. 
The transmission phase of the life cycle begins with the formation of male and 
female gametocytes. When a mosquito takes a blood meal, it ingests gametocytes, which 
mature into gametes and mate to form zygotes. The zygotes develop into motile 
ookinetes, which move through the epithelial cells that line the midgut wall and develop 
into sporozoite-forming oocysts. When the oocyst bursts, the released sporozoites invade 
the mosquito’s salivary glands, from which they will be injected into another human host, 
and the life cycle will begin again (Oaks, 1991) (Figure 1). 
Antioxidant Systems of Plasmodium 
Throughout its complex life cycle, the parasite is exposed to challenges and 
stresses. For example, the majority of parasites ingested by the mosquito will perish 
within the first 24 hours due to a number of factors, including mosquito-derived digesting 
enzymes present in the mosquito midgut and the cytotoxic byproducts of their activity 
(Alavi et al, 2003; Arambage et al, 2009). Damage may also be done to these parasites by 
the immune components of the previous vertebrate host (Margos et al, 2001). In addition, 
the mosquito mounts its own immune response against the parasite in the form of 
antimicrobial peptides as well as reactive oxygen species (ROS) and reactive nitrogen 
species (RNS), which can damage both DNA and cellular targets (Müller, 2004; Fang, 
2004).  
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In order to survive, Plasmodium must have the ability to create for itself a redox 
environment that will minimize the damage caused by these stresses, while at the same 
time allowing it to continue its own essential metabolic functions (Imlay, 2003). In order 
to maintain this redox homeostasis, the parasite relies on two main antioxidant systems, 
the glutathione system and the thioredoxin system (Figure 2), which are also conserved in 
most eukaryotes (Müller, 2004).   
 
The thioredoxin redox system consists of the oxidoreductase thioredoxin 
reductase (TrxR) and the small protein thioredoxin (Trx), which supplies electrons to 
various redox proteins, such as antioxidant thioredoxin-dependent peroxidases (Figure 2). 
The thioredoxin system transports electrons via reduction-oxidation (redox) mechanisms, 
a process that depends on thiol-containing cysteines present in the thioredoxin domain of 
these proteins. In the first step of this system, the enzyme TrxR catalyzes the reduction of 
oxidized thioredoxin [Trx-(S2)] (Holmgren, 1979; Kanzok, 2000). This leads to reduction 
of the disulfide bond in Trx and subsequent formation of two thiol groups in reduced 
thioredoxin [Trx-(SH)2].  These thiol groups can then reduce the disulfide bond in several 
target proteins, including thioredoxin-dependent peroxidases (TPx) or other disulfide-
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containing substrate proteins (Holmgren, 1995). The expanding roles of this redox system 
in Plasmodium are still a topic of study, and more evidence suggests that it may be 
essential for the parasite. For example, the knockout of thioredoxin reductase has been 
shown to be lethal to Plasmodium falciparum (Krnajski et al., 2002).  
Thioredoxin Superfamily of Proteins 
Thioredoxin and proteins that are reduced by the thioredoxin system are part of a 
larger group of proteins known as the thioredoxin superfamily. This large family is 
divided into two main groups, with Group I comprised of proteins that only contain a Trx 
domain and Group II consisting of proteins that contain a thioredoxin domain along with 
other domains (Sadek et al, 2003). The thioredoxin domain of these proteins folds into a 
characteristic three-dimensional structure known as the thioredoxin (Trx) fold (Figure 3). 
The basic structure of the Trx fold consists of an at least four-stranded beta sheet 
surrounded by at least two alpha helices (βαβββα) (Martin, 1995; Atkinson and Babbitt, 
2009).  
 
6 
 
 
 
A subset of proteins in the thioredoxin superfamily have been shown to possess 
redox activity (Atkinson and Babbitt, 2009). In general, redox activity of Trx-like 
proteins is attributed to the presence of the amino acid cysteine in the active site of the 
protein (Atkinson and Babbitt, 2009). The classical and widely conserved amino acid 
sequence, or motif, that was first identified in thioredoxin and is commonly observed in 
Trx-like proteins consists of two cysteine residues on either side of two other amino acids 
(CXXC) (Holmgren, 1985). The sulfur-containing cysteine allows the proteins to exist in 
either a reduced [Trx-(SH)2] or oxidized [Trx-(S2)] form (Holmgren, 1995). This enables 
thioredoxins to reduce substrate proteins through the process of cysteine-thiol disulfide 
exchange. Briefly, the thiolate of the peroxidatic cysteine of reduced thioredoxin [Trx-
(SH2)] allows for the nucleophilic attack of a disulfide group in a substrate protein, 
leading to a mixed disulfide. A nucleophilic attack of the deprotonated resolving cysteine 
then leads to the formation of an oxidized thioredoxin domain (Trx-[S2]) and reduced 
substrate protein (Holmgren, 1995). However, more and more variations on this classical 
active site have been found in thioredoxin fold containing proteins. Some proteins in the 
thioredoxin superfamily possess only a single cysteine in their active site, while others 
have no easily discernable active site (Atkinson and Babbitt, 2009).  
The phosducin-like family of proteins was one of these groups of proteins in 
which a catalytic motif was not readily detected (Atkinson and Babbitt, 2009). This 
family of proteins is broadly conserved, with members appearing in all eukaryotic 
organisms. Proteins belonging to this family contain a C-terminal thioredoxin domain, 
but lack the classical CXXC active site (Marchler-Bauer et al, 2009). Phosducin-like 
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proteins can be organized into three different subgroups (Willardson and Howlett, 2007). 
Subgroup I consists of phosducin (Pdc) and phosducin-like protein 1 (PhLP1). Subgroup 
II is represented in humans by two proteins, PhLP2A and PhLP2B, and in lower 
organisms by a single protein, PhLP2. Subgroup III contains PhLP3, also known as 
thioredoxin domain-containing protein 9 (TXNDC) or ATP binding protein associated 
with cell differentiation (APACD). The work presented in this project sheds new light on 
this subgroup of the thioredoxin superfamily of proteins.  
Studying Plasmodium Mosquito Stages 
As mentioned, Plasmodium is faced with particularly stressful conditions during 
its first 24 hours in the mosquito midgut due to the presence of ROS and RNS (Luckhart 
et al, 1998; Molina-Cruz et al, 2008). Once ingested by the mosquito, the parasite 
gametes leave the host red blood cell, thus switching from an intracellular to an 
extracellular lifestyle and exposing itself to the harsh environment of the mosquito 
bloodmeal. The formation of a zygote takes place within an hour of ingestion. 
Transformation from a zygote to an ookinete, however, forces the parasite to remain in 
these severe conditions for up to 20 hours (Sinden et al, 2004). And while it is 
hypothesized that members of the thioredoxin family of proteins play a role in defense 
against this oxidative stress, very little is known about their protective mechanisms 
(Nickel, 2006). A more thorough understanding of the specific functions of this protein 
family in ookinetes may provide us with an indication of how to inhibit these proteins 
and possibly prevent transmission of the parasite. 
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The mouse malaria parasite Plasmodium berghei is an excellent model system for 
studying the mosquito stages of Plasmodium for several reasons. Firstly, since P. berghei 
is not infectious to humans, infected mosquitoes can safely be studied in a lab 
environment. In addition, research with rodents does not carry the same ethical 
implications as working with humans or other primates. Importantly, it has previously 
been shown that all mammalian malaria parasites possess comparable life cycles as well 
as similar morphological features of the different life stages (Sinden, 1978). The genome 
organization between rodent-infecting parasites and human-infecting parasites is also 
conserved (Janse et al, 1994; van Lin et al, 2001). In addition, mammalian malaria 
parasites have not been found to possess any major differences in their metabolic 
pathways (Janse and Waters, 1995). And while small differences in the way each species 
interacts with its host do exist, P. berghei still provides us with a very useful starting 
point from which to research many of the unknown aspects of this parasite.  
Thesis Objective 
While studies in Plasmodium have focused on the antioxidant functions of 
thioredoxins, this group of proteins has been shown to play numerous other roles in other 
organisms, including protein folding (Ito and Inaba, 2008), cell proliferation 
(Immenschuh and Baumgart-Vogt, 2005), and signal transduction and transcriptional 
regulation (Brigelius-Flohe and Flohe, 2011). Despite these findings, some studies 
estimate that only 5.6% of proteins belonging to the thioredoxin superfamily have been 
manually associated with a function (Atkinson and Babbitt, 2009). With this in mind, the 
objective of this project was to characterize a novel thioredoxin domain-containing 
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protein of the malaria parasite P. berghei. The results presented here not only serve to 
begin to identify the function of this protein in Plasmodium, but may also provide new 
insight into the functions of related proteins in other organisms.  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Reagents 
 
All enzymes and enzyme buffers were obtained from Fermentas (Vilnius, Lithuania). 
Unless otherwise stated, all primary antibodies were obtained from Open Biosystems 
(Huntsville, AL). All PCR primers were obtained from Fisher Scientific (Fairlawn, NJ). 
 
Agilent Technologies; Santa Clara, CA: BL21 CodonPlus Competent Cells, RNace-It 
Ribonuclease Cocktail. 
 
Amresco; Solon, OH: 2-mercaptoethanol (BME), glycerol, sodium dodecyl sulfate 
(SDS), tris. 
 
Bioexpress; Kaysville, UT: agar, fetal bovine serum (FBS), nuclease-free water, tryptone, 
urea. 
 
Cell Applications, Inc.; San Diego, CA: Bovine insulin. 
 
Electron Microscopy Sciences; Hatfield, PA: Glutaraldehyde, 25% solution. 
 
Enzo Life Sciences; Farmingdale, NY: NADPH tetrasodium salt. 
 
Fisher Scientific; Fairlawn, NJ: ampicillin trihydrate, bovine serum albumin (BSA), 
calcium chloride (CaCl2), chloramphenicol, chloroform, deoxycholic acid, dimethyl 
sulfoxide (DMSO), glacial acetic acid, glycine, hydrochloric acid (HCl), imidazole, 
isopropyl β-D-1-thiogalactopyranoside (IPTG), kanamycin sulfate, potassium phosphate 
(KH2PO4), methanol, magnesium chloride (MgCl2), phenol, sodium borohydride, sodium 
chloride (NaCl), sodium hydroxide (NaOH), sodium phosphate (Na2PO4), yeast extract. 
 
Growcells.com; Irvine, CA: X-Gal powder.  
 
Jackson ImmunoResearch Laboratories, Inc; West Grove, PA: Normal Donkey Serum. 
 
Life Technologies; Carlsbad, CA: Alexa Fluor 488 Goat Anti-Rabbit IgG (H+L), Alexa 
Fluor 555 Goat Anti-Mouse IgG (H+L), Alexa Fluor 555 Goat Anti-Rabbit IgG (H+L), 
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beta-tubulin monoclonal antibody (mouse), DH5α competent E. coli, DNAse I, High 
Capacity RNA-to-cDNA kit, pRSET-A vector, Quant-iT Protein Assay Kit, Qubit RNA 
Assay Kit. 
 
Millipore; Billerica, MA: cystatin C, Millicell EZ Slide, pepstatin A. 
 
Molecular Research Center, Inc.; Cincinnati, OH: Tri-Reagent RT. 
 
MP Biomedicals; Solon, OH: 5, 5’-dithiobis-(2-nitrobenzoic acid) (DTNB). 
 
Promega; Madison, WI: dithiothreitol (DTT), pGEM-T Easy Vector System. 
 
Qiagen; Germantown, MD: E. coli M15, pQE9 vector, pQE30 vector.  
 
Sigma-Aldrich; St. Louis, MO: Bromophenol blue, Coomassie Brilliant Blue R, 
Dulbecco’s Modified Eagles Medium (DMEM), JM109 Competent Cells, 
ethylenediaminetetraacetic acid (EDTA), ethylene glycol tetraacetic acid (EGTA), 
paraformaldehyde, penicillin-streptomycin, PIPES, proteinase K, saponin, sodium azide, 
triton-X 100. 
 
Thermo Scientific: 1-Step NBT/BCIP, 6X DNA Loading Dye, DreamTaq PCR Master 
Mix, Ethidium Bromide Solution, GeneJet Gel Extraction Kit, GeneJet Plasmid Miniprep 
Kit, GeneRuler 1 kb DNA Ladder, Goat Anti Rabbit IgG Fc Alkaline Phosphatase, 
HisPur Ni-NTA Resin, lysozyme, Melon Pierce Crosslink Immunoprecipitation Kit, 
Phusion Site-Directed Mutagenesis Kit, Recombinant Protein A Agarose, Spectra 
Multicolor Broad Range Protein Ladder, TopVision LE GQ Agarose, Tubulin Beta 
Polyclonal Antibody (rabbit). 
 
Whatman; Dassel, Germany: Reinforced Nitrocellulose Membrane. 
 
Buffers, Media, and Solutions 
 
Alkaline phosphatase buffer: 100 mM NaCl, 5 mM MgCl2, 100 mM tris-HCl. 
 
BRBD80: 80 mM PIPES, 1 mM MgCl2, 1 mM EGTA, pH 6.8. 
 
Buffer B: 100 mM NaH2PO4, 10 mM tris-HCl. Adjust pH to 8 using NaOH. 
 
Buffer T: 100 mM potassium phosphate, 2 mM EDTA, pH 7.4. 
 
Calcium chloride solution: 60 mM CaCl2, 15% glycerol, 10 mM PIPES (pH 7). 
Autoclave or filter sterilize. 
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Genomic DNA (gDNA) lysis buffer: 40 mM Tris-HCl (pH 8), 80 mM EDTA (pH 8), 2 % 
SDS, 0.1 mg/mL proteinase K (add just before use). 
 
10 mg/mL insulin: Mix 50 mg bovine insulin in 4 mL 0.5 M tris-HCl (pH 8). Adjust pH 
to 2 or 3 using 1 M HCl and then rapidly titrate back to 8 using 1 M NaOH. Add dH2O to 
5 mL. 
 
Immunoprecipitation buffer: 50 mM tris-HCl, 100 mM NaCl, 1% triton-X 100, 0.5% 
deoxycholic acid, 1% BSA, 0.02% sodium azide, 0.2 mM PMSF, 40 nM cystatin C, 150 
nM pepstatin A. 
 
Immunoprecipitation lysis solution: 1% SDS, 100 mM NaCl, 0.2 mM PMSF, 50 mM tris-
HCl, 40 nM cystatin C, 150 nM pepstatin A. 
 
Immunoprecipitation wash solution: 50 mM tris-HCl, 100 mM NaCl. 
 
Insulin assay buffer: 20 mM EDTA, 100 mM KH2PO4. 
 
Luria-Bertani (LB) medium: 0.5% yeast extract, 1% NaCl, 1% tryptone. 
 
Nycodenz buffer: 300 mg Tris-HCl, 61 mg CaNa2EDTA ∙ H2O, 110 mg KCl (BDH). 
Dissolve in 450 mL H2O and adjust pH to 7.5 using 1 M NaOH. Fill to 500 mL and 
autoclave. Store at room temperature. 
 
100% Nycodenz: 55.2 g Nycodenz (Axis-Shield). Add powder to 200 mL Nycodenz 
buffer. Autoclave and keep at room temperature. Before use, mix with sterile PBS. 
 
PEM buffer: 100 mM PIPES, 1 mM EGTA, 2 mM MgCl2, pH 6.8. 
 
Phosphate-buffered saline, 10X: 1.37 M NaCl, 27 M KCl, 43 mM Na2PO4, 14 mM 
KH2PO4.  
 
100X Pyrimethamine Stock Solution (7 mg/mL): 280 mg pyrimethamine, 40 mL DMSO. 
Dissolve pyrimethamine in DMSO by vortexing for a few minutes until solubilized. The 
stock solution can be kept at room temperature and diluted in drinking water before use. 
As the pyrimethamine precipitates when adding water, the pH is lowered by adding HCl 
to the water. Pyrimethamine will be resolubilized between pH 3-5.  
 
Reservoir buffer, 10X: 0.25 M tris, 2 M glycine. 
 
Schizont culture medium: 16.4 g RPMI without HEPES, 1.75 g NaHCO3, 25 U/mL 
penicillin/streptomycin. Dissolve all ingredients in 900 mL H2O and adjust pH to 7.2. Fill 
to 1 L, filter sterilize, aliquot, and store at -20° C.  
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SDS electrophoresis buffer: 0.125 M tris, 0.96 M glycine, 0.5% SDS. 
 
SDS-PAGE sample buffer, 2X: 0.09 M tris-HCl (pH 6.8), 20% glycerol, 2% SDS, 0.02% 
bromophenol blue. 
 
TAE electrophoresis buffer: 242 g tris base, 57.1 mL glacial acetic acid, 100 mL 0.5 M 
EDTA solution (pH 8), H2O to 1 L. 
 
Accession Numbers 
 
PlasmoDB ID numbers for reported genes and proteins are as follows: 
Thioredoxin Reductase (PBANKA_082470), Thioredoxin-1 (PBANKA_132090), Trx-
469/PhLP1 (PBANKA_120480). GenBank (NCBI) ID numbers are as follows: TXNDC9 
(NM_005783.3), Thioredoxin (BC003377.1). 
 
Parasite Maintenance and Mosquito Infections 
Plasmodium berghei ANKA 2.34 parasites were maintained in Harlan ND4 mice 
for a maximum of four serial passages and passed through Anopheles stephensi 
mosquitoes.  
Cultivation of HepG2 and HeLa Cell Lines 
HepG2 cells were provided by Dr. Anwar Khan from University of Illinois at 
Chicago, and HeLa cells were provided by Father Peter Breslin from Loyola University 
Medical Center. Cells were maintained in DMEM, 10% FBS, 1% penicillin/streptomycin 
in a 37° C incubator with 5% CO2. 
Generation of Human and P. berghei cDNA 
Total RNA from P. berghei or HepG2 cells was extracted using Tri-Reagent 
according to manufacturer’s instructions. Isolated RNA was treated with DNAse I and 
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subsequently quantified using the Qubit RNA Assay Kit and the Qubit fluorometer. RNA 
samples were either immediately used for cDNA synthesis or flash frozen and stored at -
80° C. cDNA was synthesized from total RNA with the High Capacity RNA-to-cDNA 
kit using random hexamer primers. 
Isolation and Purification of P. berghei gDNA 
A 1 mL sample of mouse blood containing ~20% mixed asexual blood stages was 
centrifuged at 3000 x g for 2 minutes. The cells were washed once in cold PBS and then 
resuspended in 1 mL PBS. Saponin was added to a final concentration of 0.05% and the 
sample was gently mixed. Immediately after lysis was observed, the tube was centrifuged 
at 6000 x g for 5 minutes. The supernatant was removed and 25 μL of lysis buffer and 75 
μL distilled water were added to the pellet. The tube was then incubated at 37° C for 3 
hours with intermittent stirring. After this time, 100 μL of distilled water were added 
followed by addition of 200 μL of phenol (equilibrated with 0.1 M Tris-HCl [pH 7.0]). 
The solution was mixed well and centrifuged at 2000 x g for 8 minutes. The extraction 
was performed again with 200 μL of chloroform. 2 μL of RNace-It Ribonuclease 
Cocktail were added for 30 minutes at 37° C. The extraction was performed again with 
phenol and chloroform as above. 
The gDNA was precipitated by adding one tenth volume of 3 M sodium acetate 
(pH 5.0) and 2.5 volumes of absolute ethanol. The tube was allowed to sit for 2 hours or 
overnight at -20° C. The precipitate was centrifuged at 2000 x g for 30 minutes at 4° C 
and then gently washed once with 70% ethanol and dried in a speed-vac. The pellet was 
then resuspended in 25 to 100 μL of distilled water, depending on its size. 
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Polymerase Chain Reaction (PCR) of Target DNA 
All PCR reactions were incubated on the Eppendorf Mastercycler ep gradient S 
thermal cycler. 
TXNDC9 
The region of the human genome coding for Thioredoxin Domain-Containing 
Protein 9 (TXNDC9) was amplified using PCR from cDNA obtained from the HepG2 
human liver cell line using a forward primer with a 5’ BamHI site and a reverse primer 
with a 3’ HindIII site. The primers were as follows: 
Forward: 5’ CCGGATCCGAAGCTGATGCATCTGTTGACATG 3’ 
Reverse: 5’ CCTTTCTTTATACTAAGTCTGAGACTACTACTAATCTTCGAACC 3’ 
The following reagents: 5 μM forward primer, 5 μM reverse primer, 1:25 diluted cDNA, 
1X DreamTaq PCR Master Mix were mixed and brought to a final volume of 20 μL with 
nuclease-free H2O. The reaction was incubated on a ThermoCycler on the following 
program: initial denaturing at 94° C for 10 minutes, then 35 cycles of denaturing at 94° C 
for 30 seconds, annealing at 60° C for 45 seconds, and elongation at 72° C for 1 minute, 
with a final elongation at 72° C for 5 minutes. 
hTrx 
The region of the genome coding for human Thioredoxin was amplified using 
PCR from cDNA obtained from the HepG2 human hepatocyte line using a forward 
primer with a 5’ BamHI site and a reverse primer with a 3’ Kpn1 site. The primers were 
as follows: 
Forward: 5’ GGGGATCCGTGAAGCAGATCGAGAGCAAG 3’ 
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Reverse: 5’ CTTGAAGCCACCATTAATGAATTAGTCTAAGGTACCCC 3’ 
The following reagents: 5 μM forward primer, 5 μM reverse primer, 1:25 diluted cDNA, 
1X DreamTaq PCR Master Mix were mixed and brought to a final volume of 20 μL with 
nuclease-free H2O. The reaction was incubated on a ThermoCycler on the following 
program: initial denaturing at 94° C for 10 minutes, then 35 cycles of denaturing at 94° C 
for 30 seconds, annealing at 60° C for 45 seconds, and elongation at 72° C for 1 minute, 
with a final elongation at 72° C for 5 minutes. 
PbPhLP1 knockout construct 
The primers for the 5’ region had a 5’ ApaI site and a 3’ HindIII site. The primers 
for the 3’ region had a 5’ BamHI site and a 3’ XBaI site. The primers were as follows: 
5’ Forward: 5’ CC GGGCCC CAATGCCCCCAAAACGAAAACAGAC 3’ 
5’ Reverse: 5’ CCAAGCTT CGAATCTAAATATTCACATCTCCATGTAG 3’ 
3’ Forward: 5’ CCGGATCCGGCGGAGATAATTTTTCTGAACAAGC 3’ 
3’ Reverse: 5’ CC TCTAGA CCTCTTCATGATACCTCGATTCAAAG 3’ 
The following reagents: 1 μL genomic DNA (gDNA), 1 mM forward primer, 1 mM 
reverse primer, 1X DreamTaq PCR Master Mix were mixed and brought to a final 
volume of 25 μL with nuclease-free water. One reaction was set up for each primer pair 
and incubated in the thermal cycler on the following program: initial denaturating at 94° 
C for 10 minutes, then 35 cycles of denaturing at 94° C for 30 seconds, annealing at 56° 
C for 45 seconds, and elongation at 65° C for 45 seconds, with a final elongation at 65° C 
for 6 minutes. 
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Site-Directed Mutagenesis 
5’ phosphorylated primers were designed to mutagenize PbPhLP1 using the 
Phusion Site-Directed Mutagenesis Kit. The primers were as follows: 
PhLP1-C106S Forward: 5’ AGAAATACTACATGGAGATCGGAATATTTAGATTCG 
3’ 
PhLP1-C106S Reverse: 5’ ATAAAAATGACAACATACATTTGTTGAATTTTTAC 3’ 
Plasmid DNA was used as a template. The reaction was set up using reagents from the 
Phusion Site-Directed Mutagenesis Kit as follows: 10 pg template DNA, 10 mM dNTPs, 
1X Phusion HF Buffer, 0.5 μM forward primer, 0.5 μM reverse primer, 1 U Phusion 
HotStart II DNA Polymerase were mixed and nuclease-free water was added to 50 μL. 
The reaction was incubated on the thermal cycler on the following program: initial 
denaturing at 98° C for 2 minutes, then 25 cycles of denaturing at 98° C for 15 seconds, 
annealing at 60° C for 30 seconds, and elongation at 72° for 2 minutes, with a final 
elongation at 72° C for 10 minutes. A ligation was then performed to circularize the 
plasmid. The ligation was set up using the following reagents from the Phusion Site-
Directed Mutagenesis Kit: 1X Quick Ligation Buffer, 0.5 μL T4 DNA Ligase were mixed 
and incubated at room temperature. The ligation reaction was incubated on ice until 
transformation. 
TA Cloning of DNA Fragments into pGEM Vector 
The following reagents from the pGEM-T Easy Vector System II: 1X Rapid 
Ligation Buffer, 25 ng pGEM-T Easy Vector, 3 U T4 DNA Ligase, 1.5 μL solution 
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containing DNA fragment were mixed and brought to a final volume of 10 μL using 
nuclease-free water. The reaction was incubated overnight at 4° C.  
Making DH5α and M15 Competent Using CaCl2 
Cells were grown in 50 mL LB media (plus 0.1 mg/mL kanamycin for M15) to an 
optical density (OD) of 0.15. Optical density was measured at a wavelength of 650 nm 
using the Genesys 6 spectrophotometer (Thermo Scientific). The cells were then pelleted 
at 3500 g for 10 minutes at 4° C. The supernatant was discarded and the pellet was 
resuspended in 10 mL cold calcium chloride solution. The cells were pelleted at 3500 g 
for 5 minutes at 4° C. The supernatant was discarded and the pellet was again 
resuspended in 10 mL cold calcium chloride solution. The cells were incubated on ice for 
30 minutes and then spun down at 3500 g for 5 minutes at 4° C. The supernatant was 
discarded and the pellet was resuspended in 2 mL cold calcium chloride solution. 
Competent cells were used within 48 hours for transformation.  
E. coli Transformation (DH5α, JM109, M15, BL21) 
5 μL plasmid was mixed with 25 μL of the competent cells in a 1.5 mL 
microcentrifuge tube. The mixture was incubated on ice for 20 minutes and then heat 
shocked at 42° C for 20 seconds. The reaction was again placed on ice for 2 minutes 
before 500 μL LB media were added. The cells were then incubated in a 37° water bath 
for 1 hour. The transformed cells were spread onto plates containing LB, 1.5% agar plus 
antibiotics (0.1 mg/mL ampicillin, 0.1 mg/mL kanamycin and ampicillin, or 0.1 mg/mL 
ampicillin and 35 μg/mL chloramphenicol). In the case of blue/white screening, plates 
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containing LB, 1.5% agar plus 0.1 mg/mL ampicillin, 0.1 mM IPTG, and 20 μg/mL X-
Gal. The plates were incubated overnight in a 37° C incubator. 
Restriction Digests 
    Restriction digests were done using the following enzymes: ApaI, BamHI, 
HindIII, KpnI, XBaI. The reactions were set up according to manufacturer’s instructions.  
Ligation of Fragments into Vectors 
Ligations using vectors other than pGEM were set up using the following 
reagents: 1X T4 DNA Ligase Buffer, 1 μL vector, 16 μL DNA fragment, 0.25 U T4 DNA 
Ligase. The reaction was mixed and incubated overnight on the Eppendorf Mastercycler 
ep gradient S at 16° C.  
Protein Expression 
M15 or BL21 cells containing appropriate plasmid were grown in LB plus 
antibiotic (0.1 mg/mL ampicillin plus 0.1 mg/mL kanamycin for M15, 0.1 mg/mL 
ampicillin plus 35 μg/mL chloramphenicol for BL21) in a shaking incubator at 37° C (or 
room temperature for expression of TXNDC9). Optical density (OD) was measured at a 
wavelength of 650 nm using the Genesys 6 Spectrophotometer (Thermo Scientific) until 
an OD of approximately 0.5 was reached. IPTG was added to a final concentration of 1 
mM to induce protein expression. Cells were grown overnight at 37° C or room 
temperature while shaking.  
Protein Purification 
The bacterial culture was pelleted by centrifugation at 6000 g for 15 minutes at 4° 
C and the media was removed. Cells were then resuspended in Buffer B plus 45 mM 
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imidazole, 10 μM PMSF, and 50 μg/mL lysozyme and shaken at room temperature for 1 
hour. Bacteria were sonicated 5 times for 45 seconds and iced for at least 45 seconds 
between sonications. Cells were then spun down at 35,000 g for 30 minutes at 4° C. 
Pellets were discarded and the cell lysate was poured over a Ni-NTA column. 2 mL of 
Ni-NTA slurry was used for every 500 mL of bacterial culture. The lysate was slowly 
passed through the column so as to provide adequate time for protein to bind to the beads. 
The column was then washed and protein was eluted using an imidazole gradient.  
Urea Purification 
The bacterial culture was pelleted by centrifugation at 6000 g for 15 minutes and 
the media was removed. Cells were then resuspended in Buffer B with 8 M urea at 5 
mL/g of wet weight. This mixture was incubated for two hours at room temperature, and 
then centrifuged at 10,000 g for 30 minutes at 25° C. Cell lysate was poured over a Ni-
NTA column and was allowed to flow through the column at a rate of approximately 1 
drop every 5-8 seconds. After lysate had passed through column, 10 mL of Buffer B with 
6 M urea was added. This step was repeated with Buffer B with 4 M urea, 2 M urea, and 
1 M urea. The column was then washed with 10 mL Buffer U with 10 mM imidazole and 
10 mL Buffer U with 50 mM imidazole. Increased concentration of imidazole in Buffer 
U were added to elute the protein. 
SDS-PAGE 
All SDS-PAGE procedures were performed using the Bio-Rad PowerPac Basic 
and Mini PROTEAN II (Bio-Rad; Hercules, CA). Samples were loaded onto tris-glycine 
gels immersed in 1X SDS electrophoresis buffer. The Spectra Multicolor Broad Range 
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Protein Ladder was used to compare protein sizes to known standards. Gels were run at 
150 V for approximately 90 minutes.  
DNA Electrophoresis 
All PCRs and restriction digests were run on a gel consisting of 1% TopVision LE 
GQ Agarose in 1X TAE buffer plus 0.5 μg/ml ethidium bromide. For restriction digests, 
6X DNA Loading Dye was added to the reactions at a final concentration of 1X. 
GeneRuler 1 kb DNA Ladder was used to estimate DNA fragment sizes. The samples 
were run on a DNA electrophoresis cell at 120 V for 30 minutes. 
Construction of Transgenic P. berghei 
Production of Schizonts and Purification 
40-80 mL of schizont culture medium were supplemented with 20% Fetal Bovine 
Serum (FBS) and gassed with 5% CO2, 3% O2. A mouse of 3-5% parasitemia was bled, 
and the blood was mixed with the medium/FBS mixture. The culture was gassed as 
above. Schizonts were cultured at 37° C while being gently shaken at 50 rpm for 20 
hours. The culture was spun at 500 g, and the supernatant was discarded. The blood was 
layered on top of 55% Nycodenz/PBS and centrifuged at 300 g for 35 minutes with 
acceleration and deceleration set to 4. The interface containing parasites was transferred 
into a separate tube. Medium was added to 10-50 mL and the parasites were washed by 
spinning for 10 minutes at 720 g. The supernatant was removed almost fully, and the 
schizonts were immediately used for transfection. 
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Transfection of P. berghei with Amaxa Electroporation System 
2-3 days prior to transfection, a mouse was treated with phenylhydrazine (PH). 
The mouse was then bled, and the blood was kept at 37° C until use. For transfection, the 
Nucleofector I electroporator (Amaxa Biosystems; Cologne, Germany) and the Human T 
Cell Nucleofector Kit (Amaxa Biosystems; Cologne Germany) were used. This method 
was developed by Janse et al (Janse et al, 2006). 90 μL of Nucleofector solution were 
mixed with 20 μL Amaxa Nucleofector Supplement. 100 μL of this mixture and 1-5 μg of 
digested plasmid in 10 μL H2O were added to the schizonts. The suspension was rapidly 
transferred to an electroporation cuvette. Electroporation was performed with program 
U33. After the ‘OK’ signal appeared, the suspension was mixed with 200 μL of the pre-
warmed blood. Merozoites were allowed to invade for 20-30 minutes while shaking at 
300 rpm and 37° C in the Eppendorf Thermomixed (Eppendorf; Hamburg, Germany). 
The parasites were then injected intraperitoneally (i.p.) into a naïve mouse. 
Drug Selection 
Drug selection was started started 1 day after infection. Sulphadiazine treatment 
was applied by giving the mice the drug in drinking water at a concentration of 20 mg/L. 
Drug pressure was applied for 3 days. Pyrimethamine can be injected i.p. or given in 
drinking water. Here, the drug selection with pyrimethamine was done with drinking 
water for 3-4 days. WR99210 was injected i.p.at a concentration of 4 mg/mL 
(approximately 10 ng WR99210 per g body weight). 100 μL were given for 3-4 days. 
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Insulin Assays 
A stock solution of 10 mg/mL was made by mixing 50 mg bovine insulin in 4 mL 
0.5 M Tris-HCl (pH 8). The pH was adjusted to 2 or 3 using 1 M HCl and then rapidly 
titrated back to 8 using 1 M NaOH. dH2O was added to 5 ml. The working solution 
consisted of 1.75 mg/mL bovine insulin in assay buffer. Each assay had a volume of 600 
μL and was read on the Genesys 6 spectrophotometer. 450 μL working solution plus 150 
μL of 275-500 mM imidazole was used as a blank in each reaction. The concentration of 
imidazole in the blank and the control depended on the concentration of the imidazole 
that was used to elute the protein being tested in the reaction. For each reaction, the 
working solution was incubated for 3 minutes with DTT added to a final concentration of 
1.67 mM, 1.16 mM, or 0.833 mM in a cuvette. The absorbance was read at 650 nm. After 
3 minutes, 4-20 μM protein was added, and the contents of the cuvette were mixed every 
2 minutes to prevent precipitation from interfering with the beam of light. 20 μM BSA or 
150 μL imidazole was used in place of recombinant protein in the control reaction. The 
reactions were allowed to proceed 30-60 minutes, with readings taken every 30-60 
seconds. 
Immunoprecipitation of Protein from HeLa Cells 
Method 1 
The protocol for this method of immunoprecipitation was developed from Kopan 
et al (Kopan et al, 1996). HeLa cells were grown to confluence in 60 mm dishes. The 
media was removed, and cells were washed three times with 1X PBS. Cells were lysed 
using immunoprecipitation lysis solution. After lysis, cellular material was transferred to 
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a 1.5 mL microcentrifuge tube. Cellular material was sheared by passing the lysate 
through a 21 gauge needle approximately 10 times. The tubes were then spun at 20,000 g 
for 15 minutes at 4° C to pellet cell debris. The supernatant was transferred to new 1.5 
mL tubes. anti-PbPhLP1 antibodies were added to one tube to a final dilution of 1:600. 
Immunoprecipitation buffer was added to a final volume of 2 mL. As a control, only 
immunoprecipitation buffer and cell lysate (no antibodies) were added to a second tube. 
The tubes were then incubated overnight on a shaker at 4° C. 
250 μL of Recombinant Protein A Agarose beads were washed with 
immunoprecipitation buffer, and 50 μL bead slurry was added to each tube. The tubes 
were incubated for 3 hours at 4° C while shaking, and then briefly centrifuged to pellet 
the beads. A bent 28 gauge needle was used to remove liquid from the beads. The beads 
were resuspended in 1 mL immunoprecipitation buffer and transferred to a new 1.5 mL 
microcentrifuge tube. The beads were then washed once with 1 mL immunoprecipitation 
buffer and twice with immunoprecipitation wash solution. After final wash, all the 
remaining liquid was removed using bent 28 gauge needle. The beads were resuspended 
in 30 μL 2X SDS-PAGE sample buffer and boiled at 95° C for 10 minutes. The liquid 
was then run on a tris-glycine gel using the SDS-PAGE method. 
Modifications to Method 1 
Media was removed and plates were washed three times with 1X PBS. 300 μL 
lysis buffer was added to each plate, and lysate from all plates were combined in a single 
15 mL tube. Cells were sheared by passing the lysate through a pipette multiple times. 
The tube was centrifuged at 12,000 g for 15 minutes at 4° C to pellet cell debris, and the 
25 
 
 
 
supernatant was transferred to a 50 mL tube. 12 mL immunoprecipitation buffer was 
added. One day before harvesting cells, 150 μL bead slurry, 1 mL immunoprecipitation 
buffer, and anti-PbPhLP1 antibodies added to a final dilution of 1:500 were incubated on 
a shaker at 4° C overnight. This mixture was added to the 50 mL tube with the cell lysate, 
and the tube was incubated overnight at 4°C while shaking. The tube was centrifuged 
briefly to pellet the beads at the bottom of the tube. The supernatant was removed. The 
beads were resuspended in 1 mL immunoprecipitation buffer and transferred to a 1.5 mL 
microcentrifuge tube. The tube was centrifuged again to collect the beads at the bottom of 
the tube, and the supernatant was removed. The resin was washed once with 1 mL 
immunoprecipitation buffer and three times with wash solution. After all liquid was 
removed, 30 μL SDS loading buffer was added, and the tube was boiled at 95° C for 10 
minutes. The liquid was run on a protein gel as before, and the gel was stained with 
Coomassie. Bands were sent to be sequenced by mass spectroscopy at the University of 
Illinois at Chicago. 
Method 2: Pierce Crosslink Immunoprecipitation Kit 
Unless otherwise stated, all reagents used were from Pierce Crosslink 
Immunoprecipitation Kit. Unless otherwise stated, all centrifugation steps took place at 
1000 g for 1 minute. 
Antibody cleanup. Anti-PbPhLP1 antibodies were purified from serum using the 
Melon Gel IgG Purification Kit following manufacturers instructions. 
Binding of antibody to Protein A/G Plus Agarose. 2 mL of 1X Coupling Buffer 
was prepared for each immunoprecipitation reaction. The bottle of Protein A/G Plus 
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Agarose was gently swirled to obtain an even suspension. 20 μL of resin slurry was 
added to a spin column for each reaction. The column was placed in a 1.5 mL 
microcentrifuge tube and centrifuged. The flowthrough was discarded. The resin was 
washed twice with 200 μL 1X Coupling Buffer. The bottom of the column was gently 
tapped on a paper towel to remove excess liquid and the plug was inserted. 10 μg of 
antibody was prepared for coupling. The volume of antibody was adjusted to 100 μL with 
sufficient ultrapure water and 20X Coupling Buffer to produce 1X Coupling Buffer. This 
mixture was added to the spin column, and the screwcap was attached. The column was 
incubated on a shaker for 1 hour at room temperature. The bottom plug and cap were 
removed, and the column was placed in a collection tube and centrifuged. The resin was 
washed once with 100 μL 1X Coupling Buffer and twice with 300 μL 1X Coupling 
Buffer. The bottom of the column was tapped on a paper towel to remove excess liquid 
and the plug was inserted. 
Crosslinking bound antibody. 217 μL DMSO was added to a single tube of DSS 
to prepare 10X/25 mM solution. The solution was mixed with a pipette until the DSS was 
completely dissolved, and then diluted 1:10 in DMSO to make 2.5 mM DSS. 2.5 μL 20X 
Coupling Buffer, 9 μL 2.5 mM DSS, and 38.5 μL nuclease-free water were added to the 
column and incubated for 1 hour at room temperature while shaking. The bottom plug 
and cap were removed, and the column was placed in a collection tube and centrifuged. 
50 μL Elution Buffer was added and the column was centrifuged. The column was 
washed twice with 100 μL Elution Buffer and twice with cold IP Lysis/Wash Buffer. The 
last wash was left in the column, and the column was stored at 4° C until needed. 
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Cell lysis. The culture medium was removed and each dish was washed once with 
1X Coupling Buffer. 500 μL ice cold IP/Lysis Wash Buffer was added to the plates, and 
the plates were incubated on ice for 5 minutes with periodic mixing. The lysate was 
transferred to a microcentrifuge tube and centrifuged at 13,000 g for 10 minutes to pellet 
cell debris. The supernatant was transferred to a new tube and protein concentration was 
determined using the Quant-iT Protein Assay Kit. 
Pre-clear lysate using control agarose resin. For 1 mg lysate, 80 μL Control 
Agarose Resin slurry was added to a spin column and centrifuged to remove storage 
buffer. 100 μL 1X Coupling Buffer was added to the column, and the column was 
centrifuged. 1 mg of lysate was added to the column and shaken at 4° C for 45 minutes. 
The column was centrifuged. The column was discarded and the flowthrough was saved. 
The protein concentration was measured using the Quant-iT Protein Assay Kit.  
Immunoprecipitation. The column containing resin and antibody was 
centrifuged to remove IP Lysis/Wash Buffer. 1 mg lysate was added to the column and IP 
Lysis/Wash Buffer was added to 500 μL. The column was incubated on the shaker 
overnight at 4° C. The bottom plug and screw cap were removed and the column was 
centrifuged. The column was washed twice with 200 μL IP Lysis/Wash Buffer. The 
column was washed once with 100 μL 1X Conditioning Buffer and then placed in a new 
collection tube. 10 μL Elution Buffer was added to the column, and the column was 
centrifuged. With the column in the same collection tube, 50 μL Elution Buffer was 
added and incubated for 5 minutes at room temperature. The column was centrifuged and 
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the flowthrough was collected. The elution steps were repeated as desired for further 
samples. 
Sample preparation for SDS-PAGE analysis. 5X Lane Marker Sample Buffer 
was equilibrated to room temperature and gently mixed by inverting 5-10 times. Sample 
buffer was added to elutions to make 1X concentration of sample buffer. DTT was added 
to 100 mM and samples were boiled at 95° C for 5 minutes. Samples were allowed to 
cool to room temperature before being loaded on gel. Samples were run using the SDS-
PAGE method. The gel was stained with Coomassie, and bands were sent for sequencing 
by mass spectroscopy at the University of Illinois at Chicago. 
Modifications to Method 2 
Two columns were prepared, one containing lysate, beads, and antibody, and one 
containing only antibody and beads. 50 μg of anti-PbPhLP1 antibody was used during 
crosslinking, and wash steps were doubled in order to accommodate larger concentration 
of protein. The resulting gel was used for a Western blot. 
Western Blots 
Sample Preparation Using Parasite Lysate 
Cryotubes containing 2 mL of flash frozen blood infected with P. berghei was 
allowed to thaw at room temperature. Blood was transferred to a 50 mL tube. Cryotubes 
were rinsed with 1X PBS and the rinses were added to the 50 mL tube. 1X PBS was 
added to a final volume of 20 mL, and the tube was centrifuged at 750 g for 5 minutes. 
The supernatant was aspirated and the pellet resuspended in 20 mL 1X PBS. The tube 
was centrifuged at 800 g for 10 minutes. The supernatant was removed, cells were 
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resuspended in 20 mL 1X PBS, and red blood cells were lysed by adding saponin to a 
final concentration of 0.01%. The tube was mixed by inversion for 2 minutes and 
centrifuged at 1800 g for 10 minutes. The supernatant was aspirated and the lysis was 
repeated. The cells were then resuspended in 20 mL 1X PBS and centrifuged at 1800 g 
for 10 minutes. The supernatant was aspirated and the cells were resuspended in 1 mL 1X 
PBS and transferred to a 2 mL microcentrifuge tube. PMSF was added to a final 
concentration of 60 μM. From this, two 200 μL volumes were transferred to 1.5 mL 
microcentrifuge tubes. SDS-PAGE sample buffer was added to a final concentration of 
1X. BME was added to 0.75% to one of the tubes. Both samples were boiled at 95° C for 
5 minutes and centrifuged at 10,000 g for 10 minutes at 4° C. The samples were then run 
using SDS-PAGE. 
Sample Preparation Using Recombinant Protein 
Desired concentration of protein was used and SDS-PAGE sample buffer was 
added to a final concentration of 1X. BME was added to a final concentration of 5%. 
Samples were boiled at 95° C for 2 minutes and iced for 2 minutes before being run using 
SDS-PAGE. 
 Sample Preparation Using Purified Tubulin 
Purified porcine tubulin and PEM buffer were provided by Dr. Holly Goodson at 
Notre Dame University. Tubulin was diluted 1:1 with PEM buffer. SDS-PAGE sample 
buffer was added to a final concentration of 1X, and BME was added to a final 
concentration of 5%. Samples were boiled at 95° C for 2 minutes and iced for 2 minutes 
before being run using SDS-PAGE. 
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Transfer from Gel to Nitrocellulose 
After electrophoresis, gel was allowed to sit in reservoir buffer for 10 minutes. 
Nitrocellulose membrane was also incubated in reservoir buffer during this time. The blot 
was assembled and run while submerged in reservoir buffer using the Bio-Rad Mini 
Trans-Blot Module (Bio-Rad; Hercules, CA) at 100 V for 1 hour. 
Immunofluorescent Staining of Nitrocellulose Membrane 
After blotting, the membrane was incubated in blocking buffer (2.5 g milk powder 
in 1X PBS) for 20 minutes. Blocking buffer was poured off, and, if necessary, membrane 
was cut if different portions were to be stained using different antibodies. Primary 
antibodies (rabbit anti-PbPhLP1 or Tubulin Beta Polyclonal Antibody) were diluted using 
blocking buffer and added to membrane for one hour while shaking. Membrane was 
washed three times with 1X PBS and then placed in 1X PBS on shaker for 15 minutes. 
PBS was poured off. The secondary antibody, Goat Anti Rabbit IgG Fc Alkaline 
Phosphatase, was diluted using blocking buffer and added to membrane for 1 hour while 
shaking. Membrane was washed three times with 1X PBS. PBS was poured off and 
BCIP/NBT was allowed to incubate with membrane on shaker until bands started to 
appear. BCIP/NBT was then removed and alkaline phosphatase was added until 
membrane was just covered. Membrane was incubated in alkaline phosphatase overnight. 
Immunofluorescence 
Paraformaldehyde/Glutaraldehyde Fixation 
Media was removed and cells were washed once with 1X PBS. 3% 
paraformaldehyde, 0.25% glutaraldehyde, and 0.2% Triton X-100 in BRBD80 was added 
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to cells and allowed to incubate for 15 minutes at room temperature. Supernatant was 
removed, and cells were washed with 1X PBS. Cells were permeabilized by adding -20° 
C 100% methanol for 10 seconds, and then washed with 1X PBS. 0.5 mg/mL NaBH4 in 
1X PBS was added for 10 minutes. Cells were washed three times with 1X PBS before 
proceeding to staining. 
Glutaraldehyde Fixation 
Media was removed and cells were washed with 1X PBS warmed to 37° C. 
BRBD80 plus 0.5% Triton X-100 and 2% glycerol was added to cells for 20 seconds. 
Glutaraldehyde was added to final concentration of 0.5% and cells were shaken gently for 
10 minutes in the solution. The liquid was removed and 0.5 mg/mL NaBH4 in 1X PBS 
was added for 7 minutes. Cells were washed three times with 1X PBS and then 
permeabilized with 0.1% Triton X-100 in PBS for 15 minutes. Cells were washed again 
three times with 1X PBS before proceeding to staining. 
Antibody Staining 
Cells were blocked for 30 minutes in 0.1% donkey serum in 1X PBS. Cells were 
then washed three times with 1X PBS. Primary antibodies (rabbit anti-PbPhLP1, anti-
beta tubulin monoclonal antibody, or Tubulin Beta Polyclonal Antibody) were diluted in 
0.1% donkey serum in 1X PBS and incubated with cells for 1 hour at room temperature 
while shaking. Cells were then washed three times with 1X PBS. Secondary antibodies 
(Alexa Fluor 555 Goat Anti-Mouse, Alexa Fluor 555 Goat Anti-Rabbit, or Alexa Fluor 
488 Goat Anti-Rabbit) were diluted in 0.1% donkey serum in 1X PBS and incubated with 
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cells for 1 hour at room temperature while shaking. Cells were washed again three times 
with 1X PBS. 
Phalloidin Staining 
After permeabilization and antibody staining, phalloidin (provided by Dr. Anwar 
Khan at University of Illinois at Chicago) was applied at a dilution of 1:60 in 0.1% 
donkey serum in 1X PBS for 1 hour at room temperature while shaking. Cells were 
washed three times in 1X PBS. 
Imaging 
Images were acquired on FluoView FV1000 Confocal Laser Scanning 
Microscope (Olympus). Images were taken in XY plane and compressed around the Z 
axis. AF 488 was excited by exposure at 488 nm, and AF 555 was excited by exposure at 
555 nm, with fluorescent emissions were recorded at 530 nm and 565 nm, respectively.  
Thioredoxin System Assays 
All assays were measured in UV cuvettes using the Genesys 6 spectrophotometer. 
Unless otherwise stated, all reactions were carried out in Buffer T at room temperature in 
a final volume of 1 mL.  
For all thioredoxin assays, absorbance was measured at 340 nm. 200 μM NADPH 
and10-40 μM rPbTrx-1 or hTrx were incubated on spectrophotometer to establish a 
baseline. 50 nM PbTrxR was added, and the absorbance was read. After the reaction was 
completed, the protein to be tested was added, and the absorbance was read. 
Alternatively, the experimental protein was added before PbTrx-1. 
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Modeling 
Comparative models of the PbPhLP1 and hTXNDC9 structures were made using 
Swiss Model (http://swissmodel.expasy.org; Arnad et al, 2006). The thioredoxin-like 
domain of Homo sapiens Phosducin-Like Protein 2 (PDCL2) (PDBid: 3EVI) was 
selected as a template using a protein BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) against the sequences in the 
Protein Data Bank. The evolutionary conservation of the structures was investigated 
using ConSurf (Ashkenazy et al, 2010). The models were visualized using the VMD 
molecular graphics program (Humphrey et al, 1996).  
Phylogenetics 
Phylogenetic trees were constructed by Dr. Catherine Putonti at Loyola 
University Chicago. 
Sequence Comparison 
The PbPhLP1 and PbPhLP2 amino acid sequences, retrieved from PlasmoDB 
(Aurrecoechea et al, 2009) were aligned using EBI’s CLUSTALW2 tool online (Larkin 
et al, 2007). The conserved thioredoxin domain (phosducin (Phd)-like family, 
Thioredoxin (TRX) domain-containing protein 9 or Phd_like_TxnDC9) was identified 
within each sequence via NCBI’s Conserved Domain Database (Marchler-Bauer et al, 
2009). The sequence identity between the two sequences was calculated based upon the 
CLUSTALW alignment in BioEdit (http://www.mbio.ncsu.edu/bioedit/bioedit.html). 
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Identifying Paralogs and Homologs 
The PbPhLP1 and PbPhLP2 amino acid sequences were BLASTed against the 
NCBI nr protein database using blastp, retrieving the 1000 best hits given a word size of 
two (Altschul et al, 1997). The PbPhLP1 sequence BLAST results all had an e-value less 
than 0.002; the PbPhLP2 sequence BLAST results all had an e-value less than 0.037. 
The BLAST results were downloaded and parsed, using in-house parsers 
developed in C++, producing FASTA format files. Two FASTA format files were 
created for the PbPhLP1 and PbPhLP2 searches—the homologous sequences and the 
orthologous sequences. The homologous files include all 1000 hits for the individual 
BLAST. These files include orthologous sequences as well as paralogous sequences as 
there are many copies of the thioredoxin domain within the genomes of all species, not 
just Plasmodium. While the vast majority of the sequences returned for the BLAST 
searches encompassed more than just the thioredoxin domain, there were several smaller 
partial sequences, many of which are annotated as thioredoxins or putative thioredoxins. 
The second pair of FASTA files created contained only orthologs of PbPhLP1 and 
orthologs of PbPhLP2. The BLAST of the PbPhLP2 sequence against NCBI’s Protein 
database identified its paralog, PbPhLP1, with an e-value of 8 x 10-12, 68% coverage, and 
32% identity. Using this as our threshold, we restricted orthologs to hits with a coverage 
≥ 68% and a sequence identity >32%. 50 orthologs were identified for the PbPhLP2 
sequence and 140 orthologs were identified for the PbPhLP1 sequence.  
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Deriving Phylogenetic Trees 
Phylogenetic trees were created using MEGA 5.05 (Tamura et al, 2011). Within 
the MEGA software, the sequences were aligned via CLUSTALW using the default 
alignment parameters. All phylogenetic trees were derived using the Maximum 
Likelihood method with 100 bootstrap replications. The trees generated were then saved 
in NEWICK format and visualized using PhyloWidget (Jordan and Piel, 2008).
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CHAPTER III 
 
RESULTS 
Preliminary Data 
A screen of the Plasmodium genomics database PlasmoDB (Aurrecoechea et al, 
2009) for proteins containing a putative thioredoxin domain revealed multiple genes, one 
of which was a previously uncharacterized gene of the mouse malaria parasite 
Plasmodium berghei which our lab tentatively named pbtrx-469 (previously 
PB000469.02.0, now PBANKA_120480). The gene is located on chromosome 12 of the 
Plasmodium genome and consists of one exon and no introns (Figure 4). The protein 
consists of two domains, a predicted C-terminal thioredoxin domain and an N-terminal 
helical domain. The protein sequence lacks any predicted targeting sequence or 
transmembrane domain, causing us to hypothesize that PbTrx-469 may be cytosolic. In 
addition, while the protein sequence does contain six cysteines, it lacks the classical 
CXXC active site. Transcriptome and mass spectrometry data available on PlasmoDB 
indicated that pbtrx-469 is expressed during all life stages of the P. berghei life cycle 
(Hall et al, 2005). 
Initial work performed in our lab to characterize pbtrx-469 included quantitative 
real-time RT-PCR (qRT-PCR) to determine the relative expression of the gene (Figure 
5a). Expression was examined in blood stages, ookinete cultures, and parasites taken  
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from the mosquito midgut, and was compared to expression of P. berghei Thioredoxin-1 
(pbtrx-1). The transcript abundance of pbtrx-469 was found to be approximately a 
hundredfold lower than that of pbtrx-1 in both blood stage samples and mosquito midgut 
samples, and tenfold lower that pbtrx-1 in ookinete cultures (Figure 4a). These results 
indicate that pbtrx-469 is expressed at low levels when compared with other genes like 
pbtrx-1. In addition, qRT-PCR experiments were completed to examine how the 
transcript abundance changes during the time that the parasite is within the mosquito 
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midgut (Figure 5b). The mRNA levels at the 6 hour time point were comparatively low 
when compared to the profiles of known antioxidant genes (Turturice et al, 2013). 
 
Our lab cloned and expressed PbTrx-469 in a bacterial system. The recombinant 
protein was purified, and a band at approximately 24 kDa was observed, consistent with 
the calculated size of recombinant PbTrx-469 (Figure 6).  
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The purified recombinant protein was then sent out for polyclonal antibody production in 
rabbits (Open Biosystems, Thermo Scientific). Upon receipt, the antibody-containing 
serum was tested in a Western blot analysis with recombinant PbTrx-469 (Figure 7). The 
antibodies produced a prominent band at approximately 24 kDa, suggesting that they 
primarily bind to recombinant PbTrx-469. As a control, the antibodies were also tested 
with recombinant PbTrx-1 (Figure 7). No interaction was observed. 
 
  Immunofluorescent assays (IFAs) were then conducted to determine the 
expression pattern and subcellular localization of Trx-469 in P. berghei. The antibodies 
were used to stain the protein during different stages of the P. berghei life cycle, 
including asexual blood stages such as trophozoites (Figure 8a) and schizonts (Figure 
40 
 
 
 
8b), and mosquito stages such as ookinetes (Figure 8c), and sporozoites (Figure 8d). In 
these initial IFA images, it appears that the protein is localized close to the periphery of 
the parasite cell (Figure 8a-8d), suggesting that PbTrx-469 may be associated with the 
plasma membrane of the parasite. Interestingly, the anti-PbTrx-469 antibodies seemed to 
cross-react with components in or close to the membrane of the host red blood cells 
(Figure 8e). It was unclear whether this signal was due to an unspecific background 
signal or a more specific cross-reaction with a related protein of the mammalian host cell. 
 
While conducting research with our collaborator Dr. Shin-Ichiro in Japan, we 
conducted IFAs on human hepatocytes infected with P. berghei sporozoites using 
antibodies against several Trx-like proteins, including PbTrx-469. Interestingly, while 
anti-PbTrx-1, anti-PbTPx-1, and anti-Pb1CysPrx antibodies were parasite specific, the 
anti-PbTrx-469 antibodies seemed to be binding to a protein within the human host cells 
41 
 
 
 
as well (Figure 9). The protein appeared to be associated with the microtubular network 
of the host cell. 
 
 
The objective of this project was to further characterize this novel thioredoxin 
domain-containing protein in Plasmodium. Efforts would first be made to characterize 
pbtrx-469 using gene knockout experiments. In addition, the presence of the thioredoxin 
domain within PbTrx-469 caused us to characterize the protein biochemically. The 
second part of this project was to identify what the antibodies may be recognizing in 
human cells, and whether or not this target represented a homolog of PbTrx-469.  
Disruption of the pbtrx-469 Gene in P. berghei Parasites 
To help determine the significance and potential function of PbTrx-469 in the 
malaria parasite, I aimed to disrupt, or knockout (KO), the pbtrx-469 gene in P. berghei. 
This project was organized into two parts. My first task was to generate a DNA plasmid 
or KO construct here at Loyola. The verified construct would then be sent to our 
collaborator, Dr. Andrew Blagborough, for transfection into P. berghei parasites. Dr. 
Blagborough is a researcher in the laboratory of Dr. Robert Sinden at Imperial College 
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London, United Kingdom, and an expert in Plasmodium transfection and gene KO 
studies (Talman et al, 2011). 
Since Plasmodium is haploid during most of the erythrocytic stages of the life 
cycle, it is possible to interrupt the function of a gene through a single targeting event 
(Waters et al, 1997). This is achieved through the process of homologous recombination 
between a plasmid containing the KO construct and the target gene in the parasite 
genome (Janse et al, 2006). In general, there are two different methods for targeting a 
gene in this manner, a double crossover knockout (also known as a replacement 
knockout) or a single crossover knockout (also known as an insertion knockout) (Ménard 
and Janse, 1997). I chose to use the former method to KO pbtrx-469 (Figure 10). 
In this method, the construct includes two regions of homology to the gene, and 
recombination results in the replacement of the entire gene by the selectable marker 
(Ménard and Janse, 1997). In this approach it is impossible for the parasite to regenerate 
the wild-type gene. In the single crossover knockout, the construct includes only one 
region of homology to the gene, and recombination leads to the insertion of the entire KO 
plasmid. In this case, the entire gene is still present in the knockout parasites, however it 
is interrupted by a selectable marker. It is therefore possible for the parasite to remove the 
selectable marker and reform the wild-type (WT) gene (Ménard and Janse, 1997). I 
therefore chose to use the double-crossover method for this project in order to avoid a 
reformation of the WT pbtrx-469 gene. 
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Generation of the Knockout Construct 
I designed PCR primers that amplified two regions of the parasite genome. One 
region, the 5’ region, coded for a short stretch of the 5’ UTR as well as the beginning of 
the pbtrx-469 gene. The other region, the 3’ region, coded for a short stretch of the 3’ 
UTR as well as the end of the pbtrx-469 gene (Figure 10). The 5’ region primers were 
engineered to contain an ApaI and a HindIII restriction site, and the 3’ region primers 
were engineered with a BamHI and a XbaI restriction site. A PCR using genomic P. 
berghei DNA as template resulted in two distinct bands, one at approximately 516 base 
pairs representing the 5’ region and one at approximately 348 base pairs representing the 
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3’ region of pbtrx-469 (Figure 11a). Each DNA fragment was TA cloned into the 
bacterial pGEM T Easy vector (Promega). The resulting plasmids were sequenced and 
compared to the P. berghei genome sequence (PlasmoDB).          
A vector designed for targeted KO in P. berghei, pBS-DHFR (Donald and Roos, 
1993) was kindly provided by Dr. Andrew Blagborough (Figure 10). This vector contains 
a Dihydrofolate Reductase (DHFR) resistance cassette, which confers resistance to the 
antimalarial drug pyrimethamine (Waters et al, 1997). The pBS-DHFR vector also 
contains multiple cloning sites for the insertion of DNA. Following sequence verification, 
I cloned each region into the pBS-DHFR vector, resulting in the pBS-pbtrx-469-DHFR 
KO construct (Figure 10). 
 
The resulting plasmids were sent out for sequencing to verify the accuracy of the 
inserts. In parallel, I performed analytical restriction digests to ensure that the plasmid 
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was complete (Figure 11b). Bands at approximately 5000 and 3000 bp were observed, 
representing the KO insert and the remaining plasmid, respectively. The band at 
approximately 8000 bp represented undigested plasmid. I performed a large scale plasmid 
prep and determined DNA concentrations using a NanoDrop 2000 Spectrophotometer 
(Thermo). I then sent 10 μg of undigested plasmid and 5 μg of ApaI and XBaI digested 
plasmid to Dr. Andrew Blagborough for the second stage of this project, the transfection 
of the pBS-pbtrx-469-DHFR KO construct into P. berghei parasites. 
pbtrx-469KO Parasites Are Not Viable 
As mentioned, Dr. Andrew Blagborough at Imperial College London transfected 
parasites with the KO construct. After experiments were completed, he provided us with 
a brief description of his results. Linearized KO plasmid was transfected into purified P. 
berghei schizonts by electroporation using the Nucleofector I electroporator (Lonza AG). 
Transfected parasites were then injected intraperitoneally (IP) into naïve BLAB c mice. 
Drug selection with pyrimethamine was started one day after injection. Only transfected 
parasites that received and maintained the KO plasmid should be able to survive under 
drug pressure. Drug pressure was maintained for 3-4 days, after which time mice were 
checked for the presence of parasites. No parasites were observed following the first 
transfection. Three additional transfections were attempted with the same result. It was 
concluded that pbtrx-469 is likely essential for asexual parasite development. 
Biochemical Characterization of PbTrx-469 
The results from the gene knockout experiments suggested that pbtrx-469 is 
essential for P. berghei. Yet this extreme phenotype did not allow me to draw any 
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conclusions about the purpose this gene serves for the parasite. Since PbTrx-469 had 
previously been cloned and expressed by our lab, I decided to characterize this protein 
biochemically in order to determine whether or not the Trx domain was important for its 
function. 
Some thioredoxin and thioredoxin-like proteins reduce substrate proteins through 
the process of cysteine-thiol disulfide exchange (Nickel et al, 2006). The insulin-
reduction assay, established by Arne Holmgren (Holmgren, 1979), is a test to determine 
whether or not a protein possesses redox activity. This assay tests whether the protein is 
able to catalyze the reduction of the disulfide bonds between the A and B chains of 
insulin by the redox reagent dithiothreitol (DTT). Reduction of these bonds leads to the 
precipitation of the two chains. The resulting turbidity of the assay solution can be 
quantified using a spectrophotometer. 
PbTrx-469 Reduces Insulin in the Insulin-Reduction Assay  
Six or eight µM recombinant PbTrx-469 (rPbTrx-469) was incubated with 1 mM 
DTT and 26.4 μg bovine insulin in assay buffer. rPbTrx-1 was used as a positive control 
(Kanzok et al, 2000). A second control containing only DTT and insulin was also used. 
The reaction was run for 45 minutes. The results show that 6 μM rTrx-469 catalyzes the 
reduction of insulin at a rate of 0.0038 A/min (Figure 12). Increasing the concentration of 
rPbTrx-469 to 8 μM resulted in a 1.8 fold increase in the insulin reduction rate. As 
expected, 8 μM rPbTrx-1 efficiently reduced insulin at a rate of 0.054 A/min. In contrast, 
no significant reduction was observed in the absence of either rPbTrx-469 or rPbTrx-1 
during the time frame of the experiment. These results indicate that PbTrx-469 is redox 
47 
 
 
 
active. In addition, since the redox activity of thioredoxin-like proteins is dependent upon 
cysteine residues, I hypothesized that at least one of the cysteine residues identified in the 
primary sequence of PbTrx-469 is redox active and part of the putative active site. 
 
PbTrx-469 Exhibits Redox Activity with the Thioredoxin System 
Redox activity of PbTrx-469 in the insulin-reduction assay only indicates the 
presence of peroxidatic cysteines within the protein. The next step was therefore to test 
whether PbTrx-469 is reduced by the thioredoxin system, a vital part of the cellular redox 
network. Testing PbTrx-469 with its endogenous thioredoxin system would provide 
better information on its potential biochemical and cellular functions.  
The thioredoxin system consists of the flavoprotein thioredoxin reductase (TrxR) 
and the small redox active protein thioredoxin (Trx) (see Introduction, Figure 2). In 
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addition to cloning and expressing rPbTrx-1, our lab has also recently cloned and 
expressed rTrxR of P. berghei (Turturice et al, 2013) and established the redox activities 
of both enzymes in a thioredoxin assay (Kanzok et al, 2000; Haselton et al, 2014). 
PbTrxR utilizes electrons from the universal electron carrier NADPH reduce oxidized 
PbTrx-1 (Kanzok et al, 2002). Since NADPH, but not NADP+ exhibits an absorbance at 
340 nm, the oxidation of NADPH to NADP+ can be measured as a decrease in 
absorbance using a UV spectrophotometer. 
 
Using the thioredoxin reduction assay, I tested whether or not PbTrx-469 can be 
reduced by its endogenous thioredoxin system. If PbTrx-469 accepts electrons from the 
thioredoxin system, I should observe a decrease in absorbance indicating that electrons 
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flow from the thioredoxin system to PbTrx-469. An assay was set up in a 1 mL cuvette 
containing 200 μM NADPH and 20 μM PbTrx-1. The absorbance was measured at 340 
nm, giving a reading of 1.45 A, which was in the expected range for the concentration of 
NADPH used. No change in absorbance was detected as the reaction was allowed to 
baseline. After 2 minutes, rPbTrxR was added to the assay to a final concentration of 50 
nM. As expected, a rapid decrease in absorbance was observed, indicating that rPbTrx-1 
was readily reduced by rPbTrxR at a rate of 29.5 μM min-1 (Figure 13). The decrease in 
absorbance ended after all PbTrx-1 was reduced. I then added rPbTrx-469 to the reaction 
at a final concentration of 10 μM. The system resumed NADPH consumption with an 
initial rate of 6.5 μM min-1 (Figure 13). 
I next wanted to determine whether PbTrx-469 was reduced by PbTrxR or PbTrx-
1. To determine this, I repeated the experiment by starting the assay with a mix of 200 
μM NADPH and 10 μM rPbTrx-469. After 2 minutes of baseline I added 50 nM TrxR. 
No significant reduction was observed (Figure 13, open circles). After four additional 
minutes I added 20 μM rPbTrx-1 and observed an immediate rapid decrease in NADPH 
absorbance, indicating that PbTrx-469 accepts electrons from PbTrx-1 but not from 
PbTrxR. 
To determine the kinetics of the reaction between PbTrx-1 and PbTrx-469, I performed 
additional experiments and varied the concentration of PbTrx-1 between 10-40 μM while 
keeping the concentration constant at 10 μM. The kinetic analysis revealed that PbTrx-1 
exhibits a KM of 7.3 μM and a kcat of 1 min-1 at a PbTrx-469 concentration of 10 μM 
(Figure 14).  
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Modeling of PbTrx-469 
Redox activity of Trx-like proteins depends on the strategic position of cysteine 
residues in the three-dimensional structure of the protein (see Introduction, Figure 3). 
Since the insulin-reduction assay and thioredoxin reduction assay both confirmed that 
PbTrx-469 is redox active, and since this activity requires at least one cysteine residue 
(Holmgren, 1979), the next step was to determine the redox active cysteine and propose a 
putative active site for the protein. In collaboration with Ligin Solamen from Dr. Kenneth 
Olsen’s laboratory in the Department of Chemistry we generated a hypothetical model of 
PbTrx-469 based on the structure of the related human Phosducin-Like Protein 2 
(hPDCL2) (PDBid: 3EVI; Lou et al, 2009) (Figure 15).  
This model suggests that the thioredoxin domain of PbTrx-469 consists of five 
beta strands that form a central beta sheet, surrounded by three alpha helices. In addition, 
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a putative active site is present at the N-terminal side of helix 2 in the form of a Thr-Arg-
Trp-Cys motif. This position coincides with the position of the Cys-Gly-Pro-Cys motif 
found in classical thioredoxin proteins (Kanzok et al, 2002). Notably, the position of 
Cys106 of PbTrx-469 corresponds to that of the second cysteine in thioredoxin. In 
constrast, Thr103 takes the place of the first cysteine in the structure of Trx. 
 
Role of Cys106 in Redox Activity of PbTrx-469 
To test whether Cys106 in PbTrx-469 is indeed the redox active cysteine, I 
performed site-directed mutagenesis and mutated Cys106 to a serine (C106S) (Figure 
16). I hypothesized that if Cys106 is redox active, its mutation to a serine should result in 
a significant reduction of redox activity. 
Design of mutagenesis primers and cloning of PbTrx-469C106S. Using the 
pQE9-PbTrx-469 expression plasmid as template, I designed two tail-to-tail 5’ 
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phosphorylated primers. The forward (Fwd) primer introduced two point mutations in the 
codon, thereby changing a TGT (Cys) to a TCG (Ser). Using the Phusion Site-Directed 
Mutagenesis Kit (Thermo), I performed a PCR that produced a single band at the 
expected size of 4000 bp, representing the linearized pQE9-PbTrx-469C106S expression 
plasmid. The plasmid was ligated and transformed into competent DH5α cells for 
sequencing. It was verified that the two mutations were successfully introduced into the 
new expression plasmid. Confirmed pQE9-PbTrx-469C106S plasmids were then 
transformed into M15 expression cells (Qiagen) for subsequent protein expression as 
described in Materials and Methods. 
 
Expression and purification of PbTrx-469C106S. M15 cells selected for pQE9-
PbTrx-469C106S were grown in 1 L LB containing ampicillin and kanamycin. Protein 
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expression was induced via IPTG and recombinant PbTrx-469C106S was purified as 
described in Materials and Methods. A liter of bacterial culture typically yielded 1-2 mg 
of PbTrx-469C106S protein. An analytical SDS gel showed a prominent band at 
approximately 24 kDa, which is consistent with the previously purified wild-type PbTrx-
469 as well as the calculated molecular weight of 24 kDa (Figure 17). Another band 
observed at approximately 10 kDa was assumed to represent proteolysis products. 
 
PbTrx-469C106S shows significantly reduced redox activity in the insulin 
reduction assay. Following purification, I first tested potential redox activity of PbTrx-
469C106S in the insulin-reduction assay. To this end, I incubated 20 μM PbTrx-469C106S 
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with 8 mM DTT and 0.79 mg insulin in assay buffer. In a separate assay I used 20 μM 
wild-type PbTrx-469 instead of PbTrx-469C106S (Figure 18). As expected, 20 μM PbTrx-
469 effectively reduced insulin with a rate of reduction of 0.01 A/min for this assay. The 
insulin reduction activity of PbTrx-469C106S was significantly reduced compared to the 
wild-type protein, with a rate of reduction of 0.002 A/min. These results indicate that 
Cys106 in PbTrx-469 is redox active, supporting my hypothesis that it is part of the 
putative active site. 
 
PbTrx-469C106S is also inactive in the thioredoxin system. I next aimed to 
determine whether this mutation would also impact electron transfer between rPbTrx-1 
and PbTrx-469. Two assays were conducted in parallel, one using rPbTrx-469 and one 
using rPbTrx-469C106S (Figure 19). I set up two cuvettes, each containing a mix of 200 
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μM NADPH and 40 μM rPbTrx-1. rPbTrxR was then added to each cuvette to a final 
concentration of 50 nM. In each reaction, rPbTrx-1 was rapidly reduced by rPbTrxR at an 
initial rate of 35 μM min-1. The reactions were followed to completion. I then added 20 
μM rPbTrx-469 to the control cuvette and 20 μM rPbTrx-469C106S to the experimental 
cuvette. In the assay containing rPbTrx-469, NADPH consumption resumed at an initial 
rate of 3.38 μM min-1 (Figure 19). In contrast, no significant NADPH consumption was 
observed in the assay containing rPbTrx-469C106S, supporting my hypothesis that C106 is 
involved in the catalytic mechanism of PbTrx-469. 
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Majority of PbTrx-469 Expressed in E. coli is Insoluble 
Purification of PbTrx-469 involved lysing the bacteria that expressed the protein, 
pelleting the bacteria, and then running the lysate through a Ni-NTA column in order to 
purify the recombinant protein (see Materials and Methods). Theoretically, the majority 
of the recombinant protein should be present in the lysate. However, in some cases high 
level recombinant protein expression in E. coli may cause the bacteria to form insoluble 
protein aggregates known as inclusion bodies (Hartley and Kane, 1988). When this 
occurs, the protein aggregates must be solubilized from the bacterial pellet, and the 
proteins refolded.  
An SDS-PAGE analysis of the bacterial pellet from purification of PbTrx-469 
showed strong bands at the expected molecular weight of the recombinant protein, 
suggesting that significant amounts of PbTrx-469 may be insoluble and kept in inclusion 
bodies. A literature review revealed that researchers working on related proteins had 
encountered similar problems and had used denaturing conditions to extract the protein 
from the inclusion bodies (Stirling et al, 2006). To achieve a better yield of recombinant 
PbTrx-469, I therefore used a urea purification method when producing the protein (see 
Materials and Methods). This method allows for dissolution of the inclusion bodies by 
destroying all non-covalent interactions. The subsequent and careful removal of the urea 
then allows for the refolding of the recombinant protein.  
SDS-PAGE analyses of elutions collected using our original purification method 
revealed the presence of multiple bands in addition to the band representing PbTrx-469 
(Figure 20a). Thus, we predicted that the urea purification method would also allow for a 
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better removal of bacterial contaminants. Kinetics of the PbTrx-469 purified under the 
original conditions are also shown (Figure 20a). An SDS-PAGE analysis of urea purified 
PbTrx-469 showed fewer bands as well as a higher concentration of protein around the 24 
kDa mark (Figure 20b). Enzyme kinetics conducted using urea purified PbTrx-469 
showed a lower KM value, confirming our prediction that the urea purification method 
produced a protein sample that was both purer and more concentrated.  
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Characterization of Homologs of PbTrx-469 
IFA Studies Indicate that Anti-PbTrx-469 Antibodies Recognize a Protein 
Associated with the Cytoskeleton in Human Cell Lines 
 
The results obtained from previous immunofluorescence assays (IFAs) suggested 
that antibodies raised against the P. berghei protein Trx-469 may cross-react with one or 
several proteins in the human host cells (see Figure 8). To verify this, I cultured HepG2 
cells as well as HeLa cells. After the cells were fixed using glutaraldehyde (see Materials 
and Methods), I performed double-labeling with anti-PbTrx-469 antibodies and either 
anti-beta tubulin antibodies or phalloidin, which labels actin. Cells were analyzed using 
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confocal microscopy (Figure 21). In HepG2 cells, the anti-beta tubulin antibodies clearly 
labeled the microtubule network (Figure 21a). The anti-PbTrx-469 antibodies labeled a 
target that seemed to be very closely associated with microtubules, since the merged 
images show a high degree of overlap between the two labeled proteins (Figure 21a).  
The phalloidin stain clearly labeled the actin network (Figure 21b), however, no 
significant overlap was observed between the actin network and the target recognized by 
the anti-PbTrx-469 antibodies (Figure 21b). Similar results were observed in the HeLa 
cells (Figure 21c-f). The staining of the anti-PbTrx-469 antibodies seemed to be 
associated with the microtubular (Figure 21c-e) but not the actin (Figure 21f) network. In 
all IFAs, it appears that the anti-beta tubulin and anti-PbTrx-469 stain colocalize. In 
contrast, the anti-PbTrx-469 stain and phalloidin stain only colocalized weakly, if at all.  
Phylogenetic Analysis Reveals High Conservation of PbTrx-469 in Eukaryotcs 
A cross-reaction such as the one observed in the IFA may be due to the presence 
of a conserved protein in the two organisms. I hypothesized that the anti-PbTrx-469 
antibodies may be recognizing a homolog of PbTrx-469 in human cells. To test whether 
this may be true, a phylogenetic analysis was performed with Dr. Catherine Putonti. The 
amino acid sequence of PbTrx-469 was retrieved from PlasmoDB and compared with the 
NCBI non-redundant (nr) protein database using blastp (Altschul et al, 1997) (Figure 22). 
The BLAST results revealed that homologs of PbTrx-469 are present in most eukaryotes, 
including organisms such as Homo sapiens, Xenopus laevis, Danio rerio, Drosophila 
melanogaster, Schistosoma mansoni, and Arabidopsis thaliana (Figure 22b). The degree 
of sequence similarity between PbTrx-469 and its homologs varied, with some homologs 
60 
 
 
 
showing identities as high as 38% in Homo sapiens or 41% in Arabidopsis thaliana 
(Figure 22c).  
This alignment was used to generate a phylogenetic tree (Figure 22a) 
demonstrating the relationship between PbTrx-469 and its orthologs in eukaryotic 
organisms. Some of these homologs (in humans, Dictyostelium discoideum, Ciona 
intestinalis, and others) were annotated as phosducin-like proteins. These results caused 
us to change the annotation of PbTrx-469 to Phosducin-Like Protein 1 (PhLP1) in the 
Plasmodium database PlasmoDB (Putonti et al, 2013).  
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Interestingly, an analysis of the corresponding literature revealed that homologs 
of PbPhLP1 are hypothesized to be either directly or indirectly associated with the 
cytoskeleton in other eukaryotic organisms including C. elegans (Ogawa et al, 2004), 
Arabidopsis thaliana, and humans (Stirling et al, 2006). These reports strengthened our 
hypothesis that the anti-PbPhLP1 antibodies may cross-react with a protein associated 
with microtubules in human cells.  
The BLAST results included the human homolog, called Thioredoxin Domain-
Containing Protein 9 (hTXNDC9), which shares >50% amino acid identity with 
PbPhLP1 within the thioredoxin domain. I hypothesized that it is very likely that the anti-
PbPhLP1 antibodies cross-react with hTXNDC9 in the HeLa and HepG2 cell lines 
(Figure 21). It might therefore be possible to immunoprecipitate hTXNDC9 from HeLa 
cells using the anti-PbPhLP1 antibodies.  
Immunoprecipitation to Determine the Target(s) of Anti-PbPhLP1 Antibodies in 
Human Cells 
I performed immunoprecipitation experiments in order to determine the 
identitities of any proteins recognized by the anti-PbPhLP1 antibodies in human cells. In 
this technique, antibodies are used to isolate a protein from a solution such as a cell lysate 
(Bonifacino et al, 2001). To this end, the antibodies are attached to a substrate, such as a 
bead, and then incubated with the cell lysate. Any proteins recognized by the antibodies 
should bind, while all other proteins flow past. The protein or antibody-protein complex 
can then be eluted, or immunoprecipitated, separated using SDS-PAGE, and 
subsequently identified using mass spectrometry. 
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For this experiment, anti-PbPhLP1 antibodies were incubated with HeLa cell 
lysate and Recombinant Protein A Agarose beads, which have a high affinity for the 
constant region of the heavy chain of IgG type antibodies (Kopan et al, 1996). A tube 
containing only cell lysate and beads, but no antibody, was used as a negative control. 
Once the protein elutions were run on SDS-PAGE, this control would allow me to 
distinguish between bands resulting from background and bands resulting from 
immunoprecipitation by the antibody. 
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The Coomassie stained SDS-PAGE gel of a representative immunoprecipitation 
experiment is shown (Figure 23). In both the lanes containing the cell lysate sample and 
the negative control, a prominent band was observed around the 50 kDa mark and was 
hypothesized to represent the heavy chain of IgG (Figure 23, lane 1 and 2). A previous 
report had suggested a molecular weight of 26.5 kDa for human TXNDC9 (Stirling et al, 
2006). Therefore I hypothesized that a band I observed around the 25 kDa mark may be 
hTXNDC9 (Figure 23, lane 1). A second band around the 50 kDa mark was present in the 
lane containing the cell lysate sample (Figure 23, lane 1). This band potentially 
represented a protein dimer that was immunoprecipitated. I excised both the 25 kDa band 
as well as the second 50 kDa band and sent them to the University of Illinois at Chicago 
to be analyzed by mass spectrometry. The analysis revealed that both bands consisted of 
IgG chains, with the 50 kDa band representing the heavy chain and the 25 kDa band 
representing the light chain. However, no proteins other than IgG were detected. 
I concluded that the high amount of free antibody in the elutions was preventing 
the detection of bound protein in the pull down. I therefore tested a Crosslink 
Immunoprecipitation Kit (Pierce) for my subsequent immunoprecipitation experiments. 
In principle, this kit first irreversibly crosslinks the antibodies to the Recombinant Protein 
A Agarose beads before the cell lysate is added. Unbound antibodies are removed by 
washing before the sample cell lysate is added. After antibodies have bound to their 
respective target proteins, an elution buffer is then added, causing the protein to be 
released from the beads. The goal is to minimize the amount of unbound IgG present in 
the elutions. 
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I repeated my previous experiment with the experimental tube containing cell 
lysate and anti-PbPhLP1 antibodies crosslinked to beads. The control tube contained only 
beads and crosslinked anti-PbPhLP1 antibodies. The elutions were split between two 
separate SDS gels so that one gel could be used for a Western blot and the other gel for 
Coomassie staining, potential band excision, and subsequent mass spectrometry analysis. 
For the Western blot, samples and controls were run in duplicates for subsequent 
immunoblotting with either anti-PbPhLP1 antibodies or anti-beta tubulin antibodies. 
Proteins were separated using SDS-PAGE and then transferred to a nitrocellulose 
membrane (Figure 24). A band at approximately 50 kDa appeared in all four lanes. I 
concluded that this band corresponds to the IgG heavy chain (Figure 24, lanes 1-4). A 
band observed at 25 kDa was assumed to represent the IgG light chain (Figure 24, lane 2-
3). I also observed several bands in the lane containing the immunoprecipitation sample 
and that had been incubated with anti-PbPhLP1 antibodies (Figure 24, lane 3). A band 
seen just below the 50 kDa mark was assumed to be a potential dimer of hTXNDC9. A 
band appearing at approximately 34 kDa was also identified as a potential protein of 
interest and was sequenced (Figure 24, lane 3). A band at  55 kDa, which correlates with 
the molecular weight of both α- and β-tubulin, was present in both experimental lanes and 
was sequenced, since we hypothesized that tubulin may also be present in the pull down 
due to an interaction between hTXNDC9 and tubulin (Figure 24, lanes 2 and 4). The 
band appearing just below the 25 kDa mark in the Western blot was not visible by 
Coomassie stain and was therefore not sequenced (Figure 24, lane 3). The mass 
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spectrometry analysis reported that again IgG was the only detectable protein in all 
bands. 
 
I consulted the troubleshooting guide of the immunoprecipitation kit, and a 
number of possible solutions were proposed. First, when antibody is detected with the 
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eluted protein, this may be due to antibodies that were not crosslinked and not removed 
effectively. Increasing the number of wash steps should help improve this issue. Second, 
it may also be possible that insufficient amounts of the material used to crosslink the 
antibodies were added. I planned to implement both of these approaches in subsequent 
experiments. 
  However, while these experiments were being conducted, a review of previous 
data (Figure 21) raised the possibility that the anti-PbPhLP1 antibodies may be cross-
reacting with tubulin. My IFA analysis in human cells had suggested a potential 
association between microtubules and the protein recognized by the anti-PbPhLP1 
antibodies. However, my SDS gel analysis of parasite isolates (Figure 27) and 
immunoprecipitation experiments suggested that the anti-PbPhLP1 antibodies may 
potentially cross-react with tubulin, which could also explain the staining pattern 
observed in my IFA images (Figure 21). 
Anti-PbPhLP1 Antibodies Cross-React with Tubulin  
I sent my IFA images to Dr. Holly Goodson, a biochemist at Notre Dame 
University who is an expert on microtubules (Margolin et al, 2012), for her evaluation. 
She suggested that I test for a cross-reaction between the anti-PbPhLP1 antibodies and 
tubulin using a Western blot. She generously provided me with purified porcine tubulin 
for this purpose. 
A Western blot was performed using recombinant PbPhLP1 and porcine tubulin 
in order to test for the presence of anti-tubulin antibodies in the serum obtained from 
Open Biosystems, the company that generated the antibodies against our recombinant 
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PbPhLP1. Antibody development is usually performed in two separate rabbits. Therefore 
I tested the sera from both rabbits to determine if a contamination with anti-tubulin 
antibodies occurred in both antibody samples. 
15.8 μg of purified tubulin were transferred onto three lanes of nitrocellulose. The 
lanes were separated and immunoblotted with the anti-PbPhLP1 antibodies from one 
rabbit (Figure 25, lane 4), the anti-PbPhLP1 antibodies from the second rabbit (Figure 25, 
lane 5), or the anti-beta tubulin antibodies (Figure 25, lane 3). 0.85 μg of recombinant 
PbPhLP1 were transferred onto another two lanes of nitrocellulose and separately 
immunblotted with both sets of anti-PbPhLP1 antibodies (Figure 25, lanes 1-2). 
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In both lanes containing recombinant PbPhLP1 and immunoblotted with anti-
PbPhLP1 antibodies (Figure 25, lanes 1-2), a band was observed at approximately 24 
kDa, which is consistent with the molecular weight of rPbPhLP1. This verified that the 
antibodies, or at least a subset of the antibodies in the sera of each rabbit, detect 
PbPhLP1. In the lane containing purified tubulin and blotted with the anti-beta tubulin 
antibodies, a band was observed at approximately 55 kDa, which corresponds to the 
molecular weight of tubulin (Figure 25, lane 3). A band at approximately 55 kDa was 
also observed in both lanes containing purified tubulin that were immunoblotted with the 
anti-PbPhLP1 antibodies (Figure 25, lanes 4-5). These results indicate that both sets of 
anti-PbPhLP1 antibodies react with rPbPhLP1 (Figure 25, lanes 1-2) as well as tubulin 
(Figure 25, lanes 4-5). One explanation may be that the serum samples from both rabbits 
were contaminated with anti-tubulin antibodies. An alternative explanation may be that 
tubulin and PbPhLP1 share common epitopes that are recognized by the anti-PbPhLP1 
antibodies. However, an alignment of PbPhLP1 and P. berghei tubulins showed low 
percentages of amino acid identitites ranging from 7% (alpha tubulin) to 18% (delta 
tubulin) (Table 1). 
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To test the hypothesis that PbPhLP1 and tubulin share a common epitope, I 
conducted another Western blot analysis with two samples each of 11.8 μg recombinant 
PbPhLP1and 27.5 μg purified tubulin. After transfer to nitrocellulose membrane, the 
samples were stained with anti-beta tubulin antibodies (Figure 26).  
 
As expected, a band was observed at ~55 kDa in the lane containing purified tubulin 
(Figure 26, lane 1). In the lane containing rPbPhLP1, a band was observed at ~24 kDa, 
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consistent with the molecular weight of rPbPhLP1 (Figure 26, lane 3). These results 
indicate that PbPhLP1 is also recognized by the anti-beta tubulin antibodies. This 
supports the hypothesis that the two proteins may share similar epitopes. 
Western Blots of Parasite Lysate 
 
In order to further confirm that the anti-PbPhLP1 antibodies were developed 
against PbPhLP1, I also conducted a Western blot containing parasite lysate. Two 
samples of P. berghei cell lysate were separated using SDS-PAGE and the resulting gel 
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was blotted onto a nitrocellulose membrane (Figure 27). The samples were separated and 
each was exposed to either anti-PbPhLP1 antibodies or anti-beta tubulin antibodies.  
The banding patterns were compared. The blot that was probed with anti-beta tubulin 
antibodies showed a single prominent band at approximately 55 kDa, which corresponds 
to the molecular weight of tubulin (Figure 27, lane 1). In contrast, the blot that was 
probed with anti-PbPhLP1 antibodies showed two bands at 35 and 50 kDa as well as a 
stronger band at approximately 25 kDa (Figure 27, lane 2). We assume that the band at 
approximately 50 kDa represents tubulin, which may consist of a mix of parasite as well 
as mouse tubulin. It is unlikely that the approximately 25 and 35 kDa bands represent 
tubulin as they are not seen in the lane that was blotted with anti-beta tubulin antibodies. 
We hypothesize that the 25 kDa band represents PbPhLP1 and that the 35 kDa band 
possibly represents mouse APACD, which shares a high homology with hTXNDC9. 
However, since we were not able to sufficiently resolve the issue of potential cross-
reaction of the anti-PbPhLP1 antibodies with tubulin, we decided to use alternative 
approaches to investigate potential homologs of PbPhLP1.  
Characterization of Human TXNDC9 
I still hypothesized that the anti-PbPhLP1 antibodies recognized a homolog of 
PbPhLP1 in human cells. It seemed unlikely, given the high degree of identity between 
PbPhLP1 and its human homolog (see Figure 22), that the antibodies were only 
recognizing tubulin in the HepG2 and HeLa cells. However, I was unable to draw any 
conclusions about this hypothetical interaction using either immunoprecipitation or IFA. 
To extend our analysis of the human homolog of PbPhLP1 I therefore decided to express 
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recombinant hTXNDC9 to test whether the anti-PbPhLP1 antibodies were able to 
recognize the human homolog. 
 Cloning, heterologous expression, and purification of recombinant 
hTXNDC9. I designed PCR primers to amplify the open reading frame of human txndc9 
(NCBI accession number NM_005783.3) from human cDNA generated from HepG2 
cells. The PCR resulted in a single band just below the 700 bp marker. This corresponds 
to the calculated size of the txndc9 open reading frame (681 bp) (Figure 28). Following 
sequence verification, I cloned the gene into the bacterial pRSETA expression vector. 
The six histidines encoded by the pRSETA vector are added to the amino terminus of the 
protein, thus allowing the recombinant protein to be purified via a Ni-NTA affinity 
column. The resulting plasmid (pRSETA-hTXNDC9) was sequenced and transformed 
into BL21-Codon Plus Expression Cells (Agilent). 
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Expression of recombinant hTXNDC9 was conducted following the urea 
purification protocol and the protein was eluted using an imidazole gradient, as described 
in the Materials and Methods. Elutions were size-fractionated using SDS-PAGE (Figure 
29). Eluates showed a prominent band at approximately 35 kDa which was assumed to 
represent recombinant hTXNDC9. 
 
Anti-PbPhLP1 antibodies cross-react with recombinant hTXNDC9. A 
Western blot analysis was performed to determine if anti-PbPhLP1 antibodies cross-react 
with recombinant hTXNDC. 13.4 μg of recombinant hTXNDC9 was loaded on a gel. 
11.8 μg of recombinant PbPhLP1 and 27.5 μg of purified porcine tubulin were also 
loaded as positive controls. The samples were size-fractionated using SDS-PAGE, 
transferred onto a nitrocellulose membrane, and probed with anti-PbPhLP1 antibodies 
(Figure 30). As observed previously, a single band representing tubulin is visible at 
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approximately 55 kDa in the lane containing purified porcine tubulin (Figure 30, lane 1). 
A band representing PbPhLP1 appeared at approximately 24 kDa in the lane containing 
rPbPhLP1 (Figure 30, lane 3). Smaller bands also appeared in the lane and were assumed 
to represent proteolysis products. A band at approximately 35 kDa was observed in the 
lane containing recombinant hTXNDC9 (Figure 30, lane 2). This band corresponds to the 
Coomassie stained band observed during hTXNDC9 purification and thus strongly 
suggests that the anti-PbPhLP1 antibodies cross-react with hTXNDC9.  
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This was not surprising as the Plasmodium protein and its human homolog share 
55% amino acid identity within the thioredoxin domain (Figure 22c). We also observed 
that the blot of purified tubulin with anti-beta tubulin antibodies (Figure 30, lane 1) 
exhibited a relatively weak band when compared with the bands in lanes 2 and 3. We 
hypothesize that this was due to a deterioration of the purified tubulin sample due to 
multiple freeze-thaw cycles.  
Conservation of PbPhLP1 active site. While conducting the phylogenetic 
analysis of PhLPs (Figure 22), we also investigated whether the homologous proteins 
contained the same putative atypical active site (Thr-Trp-Arg-Cys) that I had previously 
proposed for PbPhLP1. We found that all of the Plasmodium species as well as the oyster 
pathogen Perkinsus marinus contained the same active site motif of Thr-Trp-Arg-Cys 
(position 103-106 in PbPhLP1 alignment, Figure 31a). Fifty-six percent of the PbPhLP1 
homologs, those in other protozoans, nematodes, insects, and vertebrates, including 
human, had a putative active site consisting of [Thr-X-Arg-Cys]. Other frequently 
observed and conserved motifs include [Ser-X1-Arg-Cys], [Thr-X1-X2-Cys], [Ser-X1-
X2-Cys], [X1-X2-Arg-Cys], and [X1-X2-X3-Cys]. The fourth position cysteine was 
found to be conserved throughout the 140 PbPhLP1 homologous sequences examined. 
Since I had determined that PbPhLP1 is redox active and accepts electrons from 
the thioredoxin system (see Figures 12-13), I hypothesized that the presence of this 
conserved cysteine motif indicates potential catalytic activity of the homologous proteins. 
In collaboration with Dr. Olsen’s lab we generated a hypothetical model of hTXNDC9 
based on the previously published crystal structure of hPDCL2 (PDB ID: 3EVI; Lou et 
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al, 2009) (Figure 31b). The model shows that Cys104 of hTXNDC9 corresponds to the 
second cysteine in thioredoxin in terms of relative position in the structure and therefore 
to Cys106 in PbPhLP1 (see Figure 15). This model suggests that Cys104 may be part of a 
solvent-accessible active site in hTXNDC9. I therefore decided to test the purified 
recombinant protein for redox activity. 
 
Recombinant hTXNDC9 is active in the insulin reduction assay. I first tested 
recombinant hTXNDC9 in the insulin-reduction assay. Twenty μM recombinant 
hTXNDC9 was incubated with 1.16 mM DTT and 0.78 mg bovine insulin in assay 
buffer. 10 μM of PbTrx-1 was used in a separate reaction as a positive control (Kanzok et 
al, 2000). 20 μM PbPhLP1 was also used as a positive control. 20 μM BSA was used as a 
negative control (Figure 32). As previously observed, both PbTrx-1 and PbPhLP1 were 
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able to catalyze the reaction between DTT and insulin, with rates of 0.455 A/min and 
0.03 A/min, respectively (Figure 32). No significant reduction occurred in the presence of 
BSA. Recombinant hTXNDC9 was also able to reduce insulin at a rate of 0.033 A/min 
(Figure 32). These results demonstrate that hTXNDC9 effectively catalyzes the reaction 
between DTT and insulin. 
 
Thioredoxin reduction assay. After observing that hTXNDC9 possesses redox 
activity, the next step was to determine if this protein is able to accept electrons from the 
thioredoxin system. Human Thioredoxin (hTrx) was also expressed and purified for this 
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purpose. The oxidation of NADPH to NADP+ by the thioredoxin system was measured at 
340 nm using the Genesys6 UV-VIS Spectrophotometer (Thermo).  
 
Two hundred μM NADPH and 10 μM hTrx were incubated in a cuvette. The 
reaction was started when rPbTrxR was added to a final concentration of 50 nM. 
Recombinant hTrx was rapidly reduced by rPbTrxR (Figure 33). The reaction was 
followed to completion. After the reaction came to an end, hTXNDC9 was added to a 
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final concentration of 10 μM. The system resumed NADPH consumption with an initial 
rate of 7.7 μM min-1 (Figure 33). These results provide evidence that hTXNDC9 is acting 
like a true member of the thioredoxin system as it is redox active and can receive 
electrons from thioredoxin. 
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CHAPTER IV 
DISCUSSION 
The purpose of this study was to characterize a novel Trx domain-containing 
protein, known initially as Trx-469, of the rodent malaria parasite Plasmodium berghei. 
In our phylogenetic study, we have identified homologs of Trx-469 in most eukaryotic 
organisms (Putonti et al, 2013). Homologs in Homo sapiens, Dictyostelium discoideum, 
Ciona intestinalis, and others were annotated as phosducin-like proteins. Since the 
nomenclature used for these proteins is oftentimes confusing, a table identifying these 
proteins has been included for the sake of clarity (Table 2).  
 
Due to the high homology with proteins of the phosducin-like family of proteins 
we designated Trx-469 as Plasmodium berghei Phosducin-Like Protein 1 (PbPhLP1), 
since it is the first phosducin-like protein to be identified in Plasmodium. We identified 
two additional PhLPs within the Plasmodium genome. However, this project focuses on 
the experimental characterization of PbPhLP1. In response to our publication, the 
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Plasmodium database PlasmoDB has reannotated orthologs of PbPhLP1 from putative 
thioredoxins to putative phosducin-like proteins in all Plasmodium species. 
In addition to its high level of conservation among eukaryotes, my results also 
suggested that this gene may play an essential role in the malaria parasite. Four 
successive attempts to knockout (KO) phlp1 in P. berghei did not produce viable 
parasites. This strongly suggests that this gene is essential for blood stages of the malaria 
parasite. This is in contrast to studies in the amoeba Dictyostelium discoideum where the 
disruption of PhLP3 had no effect while the knockout of PhLP1 caused impairment of G 
protein signaling and the knockout of PhLP2 was lethal (Blaauw et al, 2003). However, 
in other organisms RNAi and siRNA knockdown, which, in contrast to a genetic 
knockout, targets mRNA to reduce the product of a gene rather than completely removing 
it, led to significant cellular defects. For example, RNAi knockdown of C. elegans 
C05D11.3 caused abnormal microtubules and defects in cytokinesis (Ogawa et al, 2004). 
Similar results were obtained from RNAi studies of Arabidopsis thaliana PhLP3 
(Castellano and Sablowski, 2008), while siRNA knockdown of mammalian PhLP3 
resulted in an elongation of cells and nuclei due to alterations in the cytoskeletal network 
(Hayes et al, 2011). The results of these studies suggest that siRNA or RNAi may 
provide more insight into the function of phlp1. However, since RNAi studies are not 
possible in Plasmodium (Baum et al, 2009), other methods are necessary in order to 
explore potential roles for this protein in the parasite. 
We decided to characterize this protein biochemically due to the presence of the 
thioredoxin domain in the sequence. My insulin-reduction assay shows that recombinant 
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PbPhLP1 effectively catalyzes the reduction of insulin by DTT, indicating the presence 
of at least one redox active cysteine (Holmgren, 1979). PbPhLP1 is the first member of 
the phosducin-like family of proteins that has been demonstrated to be redox active.  
While homologs of PbPhLP1 have been expressed by other researchers, the experiments 
conducted in these studies have focused more on the function of the protein at the cellular 
level. Human TXNDC9 has previously been expressed as a fusion protein to investigate 
protein-protein interactions with the chaperonin containing TCP-1 (CCT) in vitro 
(Stirling et al, 2006). However, this research marks the first time that an enzymatic 
activity has been demonstrated for any member of the phosducin-like family of proteins. 
Although the insulin assay indicates redox activity, it is only useful as an artificial 
in vitro assay to detect the presence of redox active cysteines in a protein. Significantly, 
PbPhLP1 also shows activity in the thioredoxin-reduction assay. More specifically, I 
demonstrated that electrons are passed between PbTrx-1 and PbPhLP1, making PbPhLP1 
a potential target for PbTrx-1 in vivo. This activity was observed for proteins purified 
under both native and denaturing conditions, indicating that denaturing conditions had no 
adverse effects on the activity of the protein. Furthermore, the kinetic data of native and 
urea purified PbPhLP1 showed a KM value of 7.26 μM with PbTrx-1, a value that is 
highly comparable to KM values of Plasmodium Trx-1 with other Trx-like proteins 
(Nickel et al, 2006).  
An examination of the amino acid sequence of PbPhLP1 revealed that this protein 
contains six cysteine residues in its primary sequence. Of these residues, only the 
cysteine present at position 106 in PbPhLP1 was conserved in all organisms included in 
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our phylogenetic analysis (Putonti et al, 2013). Furthermore, our hypothetical model of 
PbPhLP1 in combination with the sequence analysis indicated that Cys106 may be part of 
a putative TXXC active site that occupies a solvent-accessible position in PbPhLP1. This 
putative TXXC active site is in the same relative position in the predicted three-
dimensional structure as the CXXC active site of Trx, with Cys106 corresponding to the 
C-terminal cysteine in Trx while Thr103 occupies the position of the N-terminal cysteine. 
Site-directed mutagenesis of Cys106 significantly reduced the redox activity of PbPhLP1 
in the insulin-reduction assay as well as in the thioredoxin-reduction assay, indicating 
that Cys106 is involved in the redox activity of PbPhLP1. This also supports my 
hypothesis that this cysteine belongs to the putative active site which we proposed 
(Putonti et al, 2013). 
This putative TXXC active site within the thioredoxin domain is highly conserved 
in PbPhLP1 homologs in protozoans, nematodes, insects, and vertebrates, including 
human TXNDC9 (Putonti et al, 2013). While PbPhLP1 possesses six cysteine residues in 
its structure, sequence analysis showed that hTXNDC9 possesses only three. Yet our 
hypothetical model of hTXNDC9 placed the conserved cysteine (Cys104) at the same 
position as Cys106 in PbPhLP1 and the C-terminal cysteine in Trx. We therefore 
hypothesized that hTXNDC9 may also possess redox activity. This hypothesis was 
confirmed first in the insulin-reduction assay, where recombinant hTXNDC9 displayed a 
redox activity similar to that of recombinant PbPhLP1. In addition, hTXNDC9 was 
shown to accept electrons from its endogenous thioredoxin, and the kinetic values 
between the Plasmodium and human proteins were comparable. These results represent 
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an important finding for hTXNDC9, as the possibility of redox activity of the TXNDC9 
homolog in C. elegans, C05D11.3, has previously been dismissed due to the lack of a 
characteristic CXXC active site motif (Ogawa et al, 2004). Our results indicate the 
possibility that all PbPhLP1 homologs may possess redox activity. It may therefore be 
necessary for potential functions and mechanisms to be reconsidered in light of these 
findings.  
In addition, a previous study of thioredoxin domain containing proteins using 
computational structure-based approach did not report on any active site motif in 
members of the phosducin-like family of proteins (Atkinson and Babbitt, 2009). While 
most of the characterized redox active thioredoxins contain a characteristic CXXC active 
site motif, it has been shown that a number of thioredoxins or thioredoxin-like proteins 
either lack the N-terminal or C-terminal cysteine or do not contain an apparent active site 
(Herrero and de la Torre-Ruiz, 2007). These so-called atypical active sites commonly 
contain serine or threonine residues in place of one of the cysteines (Atkinson and 
Babbitt, 2009). This appears to be the case for PbPhLP1 and hTXNDC9, since threonine 
is present in place of the N-terminal cysteine in both proteins. 
We are confident that the reduction of redox activity observed when PbPhLP1 is 
mutated is due to the absence of the redox active Cys106 rather than a change in the 
structure of the protein for the following reasons. Stabilizations of protein structures by 
disulfide bridges rarely occurs in cytoplasmic proteins due to the reducing nature of the 
cytoplasm (Alberts et al, 2008). Our own observations in Plasmodium parasites 
combined with previous reports on PbPhLP1 homologs indicate an intracellular rather 
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than extracellular localization of these proteins. Our hypothetical models of PbPhLP1 and 
hTXNDC9 also suggest that the conserved redox active cysteine is located on the surface 
of these proteins rather than buried within the structure. It therefore seems unlikely that 
the mutation of this cysteine to a serine would introduce any sort of significant 
conformational change in the protein that may account for the decrease in redox activity. 
While the results of my investigations of the cellular expression of PbPhLP1 were 
inconclusive, my observations also suggest that there may be epitopes that are conserved 
between PbPhLP1 and tubulin. My Western blot analyses show that anti-PbPhLP1 
antibodies cross-react with purified tubulin. My IFAs also show that the anti-PbPhLP1 
antibodies clearly stain the microtubular network of human cells. In addition, Western 
blots showed that anti-beta tubulin antibodies cross-react with recombinant PbPhLP1. 
However, the anti-PbPhLP1 antibodies were also able to recognize recombinant 
hTXNDC9 on a Western blot, suggesting that at least some of the staining pattern 
observable in the IFAs may be due to hTXNDC9. These results do not represent the first 
time that a cross-reaction was observed between cytoskeletal elements and antibodies 
developed against a member of the phosducin-like family of proteins (Piotrowska and 
Adler, 2010). Since PbPhLP1 may interact with tubulin in vivo, a further exploration of a 
common epitope between the two proteins is warranted. However, for the purpose of this 
project, these results only serve to suggest that the polyclonal PbPhLP1 antibodies are not 
useful for studies of PbPhLP1. However, considering the possibility of common epitopes 
between PbPhLP1 and tubulin, a logical future step would be the development of a 
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monoclonal antibody against PbPhLP1 to advance cellular studies and the investigation 
of putative interactions between this protein and the cytoskeletal network. 
The reason we pursued a possible interaction between PbPhLP1 and the 
cytoskeleton was that other studies also pointed to an interaction between PbPhLP1 
homologs and the cytoskeleton. As mentioned, disruption of this protein in both C. 
elegans and A. thaliana led to observable defects in the microtubular network of these 
organisms (Ogawa et al, 2004; Castellano and Sablowski, 2008). In A. thaliana, PhLP3 
was shown to be required for the microtubule-dependent steps of cell division (Castellano 
and Sablowski, 2008). It is my hypothesis that the KO of phlp1 in P. berghei may 
therefore have been lethal because the integrity of the cytoskeletal network had been 
compromised, ultimately leading to cell death. An alternative method to investigate the 
cellular function of phlp1 would be overexpression of the gene. This method has been 
shown to cause microtubule disassembly and an imbalance of α and β tubulin subunits in 
a mammalian system (Hayes et al, 2011).  
My hypothesis that PbPhLP1 is involved in maintenance of the cytoskeleton is 
based on observations that members of the thioredoxin-like family of proteins can 
interact with cytoskeletal components. For example, the tubulin heterodimer contains a 
high number of cysteine residues (20 in the mammalian protein) and may therefore be 
susceptible to oxidative stress (Lowe et al, 2001; Luduena et al, 1991). Oxidation of key 
cysteine residues by reactive oxygen species (ROS) leads to tubulin disulfide formation 
and subsequent loss of function due to the inhibition of tubulin polymerization (Landino 
et al, 2004). Since ROS are a common occurrence in cells, the microtubules would 
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require a maintenance and repair system in cells that reduces these destabilizing disulfide 
bridges. One study reports that the thioredoxin system can maintain the stability of 
microtubules in vitro by keeping the cysteines present in tubulin in a reduced state. 
(Landino et al, 2004). Similar findings were shown for the microtubule-associated 
proteins tau and microtubule-associated protein-2 (MAP-2) (Landino et al, 2004). 
Peroxynitrite and hydrogen peroxide caused the oxidation in these proteins, leading to a 
decreased ability to promote microtubule assembly from tubulin subunits. Treating 
oxidized tau and MAP-2 with the thioredoxin system restored their ability to promote 
microtubule assembly. These findings show that disulfide bonds present in both tubulin 
and microtubule-associated proteins may be reduced by the thioredoxin system. 
Therefore these studies suggest that the redox activity that we observed for 
PbPhLP1 and hTXNDC9 may be important for some function involving an interaction 
with tubulin, a hypothetical interaction supported by previous studies (Blaauw et al, 
2003; Ogawa et al, 2004; Castallano and Sablowski, 2008). In addition, one study on 
hTXNDC9 suggested that this protein may be involved in the CCT-mediated folding of 
tubulin subunits (Stirling et al, 2006). Further experiments are necessary in order to 
confirm the findings in this study and also to determine if the activity of this protein plays 
any role in this putative function. 
While KO experiments in S. cerevisiae and D. discoideum suggested this protein 
was not essential for the survival of these organisms (Flanary et al, 2000; Blaauw et al, 
2003), we hypothesize that the difference between my KO results and the results from 
these experiments are due to a difference in the putative active sites of these proteins. S. 
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cerevisiae was notably absent from our phylogenetic tree, suggesting that this protein in 
yeast may not be a homolog of PbPhLP1 or hTXNDC9. In addition, a recently 
constructed phylogenetic tree rooted on the putative active site of PbPhLP1 placed fungi, 
including D. discoideum, in a different clade of the tree entirely. This suggests that 
differences in the putative active sites of these proteins may be linked with differences in 
their roles in their respective organisms. Therefore, D. discoideum PhLP3 may not be 
redox active or have an important function in this organism, while other eukaryotic 
homologs that are present in different clades than D. discoideum in this tree may be redox 
active and essential for these species. These findings should therefore be taken into 
account when studying potential functions of these proteins. 
In conclusion, this project identifies PbPhLP1 as a highly conserved novel 
thioredoxin domain-containing, phosducin-like protein that is essential for the malaria 
parasite P. berghei. PbPhLP1, as well as its human homolog hTXNDC9, was shown to be 
redox active as well as able to accept electrons from the thioredoxin system. This project 
represents the first biochemical characterization of any phosducin-like protein. The 
results presented here provide insights into the functional mechanism of these highly 
conserved proteins.  
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